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SUMMARY 
_______________________________________________________ 
 
Allergic rhinitis and nasal polyposis are both chronic nasal inflammatory diseases. The 
inflammatory response shows a lot of similarities such as elevated IgE, elevated IL-5 and 
eosinophilia. The magnitude of inflammation is however a lot more prominent in nasal 
polyposis. Current treatment is often unsatisfactory. Human tissue models may be helpful to 
accelerate testing of new pharmaceutical molecules.  
 
First of all, in both nasal polyps and inferior turbinates, we established a whole tissue nasal 
mucosal stimulation model which can be used to mimic the early phase of an allergic reaction. 
By using whole tissue preparations without enzymatic digestion, the cells remained in their 
natural environment, and unchanged surface receptor expression was maintained, thus closely 
mimicking the in vivo situation. The induced concentration-dependent release of histamine, 
LTC4/D4/E4 and PGD2 after 30 minutes’ stimulation with anti-IgE, was significantly higher in 
the nasal polyp group compared to the inferior turbinate group, although tryptase, FcRI 
positive cells and FcRI-chain transcripts were equally present in both groups. 
Secondly, we established a nasal polyp tissue stimulation model with SEB for late-phase 
release of numerous immunoregulatory and proinflammatory cytokines. SEB stimulation for 
24 hours (late-phase) resulted in a significant increase of IFN-, IL-2, IL-4, IL-5, IL-10, IL-
13, TNF- and IL-1 in nasal polyps and inferior turbinates. Furthermore, in this study we  
elucidated the disease-modifying role of S. aureus derived proteins SEB, SpA and LTA in 
nasal polyps. SpA induced mast cell degranulation, whereas SEB induced the release of 
numerous immunoregulatory and pro-inflammatory cytokines, favouring Th2-cytokines and 
disfavouring IL-10 and TGF-1 in nasal polyps, supporting the modifying role of 
superantigens in the development of this inflammatory disease. 
 
These models allowed us to test new compounds in human disease relevant tissue in a pre-
safety and pre-clinical setting. Drugs targeting kinases have become the focus of a large 
number of drug discovery programs in the pharmaceutical and biotech industry. We tested 
two kinase inhibitors, namely a Syk inhibitor and an IKK-2 inhibitor. In cord blood-derived 
mast cells the Syk inhibitor significantly prevented the degranulation, assessed by 
measurement of histamine release, and the production of LTC4/LTD4/LTE4 and PGD2. The 
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Syk inhibitor was similarly able to significantly inhibit histamine, LTC4/LTD4/LTE4 and 
PGD2 in nasal polyp tissue in a dose dependent manner. Syk inhibitors might provide a new 
therapeutic possibility in the treatment of upper airway diseases with mast cell involvement, 
such as allergic rhinitis. 
IKK-2 inhibition can result in the blockage of transcription of multiple inflammatory 
mediators, such as TNF-, interleukins, cell adhesion molecules, etc. We determined, in nasal 
polyposis, the impact on the release of several Th1, Th2 and pro-inflammatory cytokines 
when inhibiting IKK-2 in comparison to the impact of the topical corticosteroid fluticasone 
propionate. Our results suggest that the IKK-2 inhibitor seemed, in certain aspects, to possess 
a more comprehensive anti-inflammatory profile than that of fluticasone propionate in nasal 
polyposis.  
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SAMENVATTING 
_______________________________________________________ 
  
Allergische rhinitis en nasale polyposis zijn beiden chronische nasale inflammatoire 
aandoeningen. Hun inflammatoir patroon vertoont vele gelijkenissen zoals gestegen IgE, 
gestegen IL-5 en eosinophilie. De ernst van de aandoening en de grootte van inflammatie zijn 
echter prominenter in nasale polyposis. De huidige behandelingen schieten af en toe tekort 
met daarom de nood aan het op punt stellen van weefselmodellen waarop nieuwe 
farmaceutische moleculen kunnen worden uitgetest.  
 
Wij konden twee modellen op punt stellen. Ten eerste konden we een stimulatiemodel op punt 
stellen, dat de vroege fase van een allergische reactie nabootst, zowel in nasale poliepen als in 
concha inferiores. Er werden weefselfragmentjes gebruikt zonder enzymatische digestie. Op 
die manier bleven de cellen in hun natuurlijke omgeving, bleven de celreceptoren bewaard en 
kon de in vivo situatie zo goed mogelijk nagebootst worden. Het bleek dat de geïnduceerde 
concentratie-afhankelijke vrijstelling van histamine, LTC4/D4/E4  en PGD2 na 30 minuten 
stimulatie met anti-IgE significant hoger was in de neuspoliep groep in vergelijking met de 
concha inferior groep. Echter, tryptase-, FcRI positieve cellen en FcRI-chain transcripts 
waren evenveel aanwezig in beide groepen.  
Ten tweede, konden we een “late-fase” model op punt stellen, waarbij neuspoliepweefsel met 
SEB gestimuleerd werd en waarbij talrijke immunoregulatoire en pro-inflammatoire cytokines 
vrijkwamen. Stimulatie met SEB gedurende 24 uur (late fase) resulteerde in het significant 
vrijgeven van IFN-, IL-2, IL-4, IL-5, IL-10, IL-13, TNF- en IL-1 in neuspoliepen en 
concha inferiores. Vervolgens konden we in deze studie de rol van S. aureus-  afgeleide 
eiwitten zoals SEB, SpA en LTA verder toelichten. SpA induceerde mastcel degranulatie en 
SEB was verantwoordelijk voor het vrijgeven van talrijke immunoregulatoire en pro-
inflammatoire cytokines, met een voorkeur voor het vrijgeven van Th-2 cytokines en met een 
minder vrijkomen van IL-10 en TGF-1. Deze resultaten ondersteunen de rol van 
superantigenen in de ontwikkeling van nasale polyposis. 
 
Deze modellen maakten het mogelijk om nieuwe moleculen te testen op humaan ziekte- 
relevant weefsel in een pre-safety en pre-clinical setting. Heel wat onderzoek in de 
farmaceutische en biotechnische industrie is momenteel gefocust op moleculen gericht tegen 
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kinases. Wij hebben twee kinase-inhibitoren uitgetest, namelijk een Syk-inhibitor en een IKK-
2 inhibitor. De Syk-inhibitor kon het vrijkomen van histamine, LTC4/LTD4/LTE4 en PGD2 
significant inhiberen in mastcellen gekweekt uit navelstrengbloed. Gelijklopend kon de Syk-
inhibitor histamine, LTC4/LTD4/LTE4 en PGD2 significant inhiberen in nasale poliepen. Syk-
inbibitoren zouden in de toekomst een nieuwe therapie kunnen vormen in de behandeling van 
bovenste luchtweg infecties, waarbij de mast cel een belangrijke rol speelt, zoals allergische 
rhinitis.  
IKK-2 inhibitie kan leiden tot het blokkeren van de transcriptie van verscheidene 
inflammatoire mediatoren, zoals TNF-, interleukines, cel-adhesie moleculen enz. In 
neuspoliepen werd de impact van een IKK-2 inhibitor op het vrijgeven van verschillende Th1, 
Th2 en pro-inflammatoire cytokines bepaald en deze impact werd vergeleken met fluticasone 
propionaat. Onze resultaten toonden aan dat de IKK-2 inhibitor op bepaalde vlakken een 
uitgebreider anti-inflammatoir profiel heeft in vergelijking met fluticasone propionaat.  
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 RESUME 
_______________________________________________________ 
  
La rhinite allergique et la polypose naso-sinusienne sont toutes les deux des affections 
inflammatoires chroniques. Leur réponse inflammatoire présente de nombreuses similitudes 
comme des taux d’IgE et d’IL-5 ainsi qu’une éosinophilie élevés. Cependant, la gravité de 
l'affection et l'importance de l'inflammation sont de plus grande ampleur pour la polypose. 
Les traitements actuels ne sont pas toujours à la hauteur d’où la nécessité de mettre en place 
un modèle tissulaire sur lequel de nouvelles molécules pharmaceutiques pourraient être 
testées.  
 
Premièrement, nous avons pu établir un modèle de stimulation aussi bien pour les polypes 
nasaux que pour le cornet nasal inférieur, pour simuler la phase initiale d'une réaction 
allergique. Des fragments tissulaires sans digestion enzymatique ont dans cette optique été 
utilisés. De cette façon, les cellules restent dans leur environnement naturel, les récepteurs 
cellulaires sont conservés et la situation in vivo a pu être simulée de la meilleure façon 
possible. La libération d'histamine, LTC4/D4/E4  et PGD2 concentration-dépendante après 30 
minutes de stimulation avec anti-IgE, était significativement plus élevée dans le groupe des 
polypes nasaux que dans celui du groupe du cornet inférieur. Néanmoins, les cellules tryptase 
ou FcRIpositiveset les transcriptions de chaînes FcRI étaient présentes dans les deux 
groupes.  
Deuxièmement, nous avons pu établir un modèle d'une “phase tardive” au cours de laquelle 
les tissus des polypes nasaux ont été stimulés avec SEB et pour laquelle quantité de cytokines 
immunorégulatrices et proinflammatoires ont été libérées. La stimulation pendant 24 heures 
(phase tardive) avec SEB a entraîné la libération significative d'IFN-, IL-2, IL-4, IL-5, IL-10, 
IL-13, TNF- et IL-1  pour les polypes nasaux et le cornet inférieur. Ensuite, nous avons pu 
expliquer plus largement dans cette étude le rôle des protéines dérivées de S. aureus comme 
les SEB, SpA et LTA. La SpA a engendré une dégranulation des mastocytes et SEB fut 
responsable de la libération de nombreuses cytokines immunorégulatrices et 
proinflammatoires, avec une prédominance notée pour la libération des cytokines Th-2 et une 
libération moindre d'IL-10 et TGF-1. Ces résultats confirment le rôle des superantigènes 
dans le développement des polypes nasaux.   
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Ces modèles nous ont permis de tester de nouvelles molécules sur des tissus humains 
sensibles à la maladie dans des conditions précliniques avant étude de tolérance. Beaucoup de 
recherches dans l'industrie pharmaceutique et biotechnique sont actuellement ciblées sur des 
molécules détruisant les kinases.  
Nous avons testés deux inhibiteurs de kinase, soit un inhibiteur de Syk kinase et un inhibiteur 
IKK-2. L'inhibiteur de Syk kinase a pu inhiber la libération d'histamine, de  LTC4/LTD4/LTE4 
et PGD2 de façon significative dans des mastocytes cultivées à partir de sang provenant de 
cordon ombilical.  
Au même niveau, l'inhibiteur de Syk kinase a pu significativement inhiber l'histamine, les  
LTC4/LTD4/LTE4 et PGD2 dans le cas des polypes nasaux. Les  inhibiteurs de Syk kinase 
devraient dans le futur former un traitement pour les infections des voies respiratoires 
supérieures, auprès duquel les mastocytes jouent un rôle important, comme la rhinite 
allergique. 
L'inhibition IKK-2 peut conduire au blocage de la transcription de différents médiateurs 
inflammatoires, comme les interleukines TNF-, les molécules d'adhésion cellulaire, etc... Au 
niveau des polypes nasaux l'impact de l'inhibiteur IKK-2 sur la libération de différents Th1, 
Th2 et cytokines pro-inflammatoires a été analysé et cet impact a été comparé à celui du 
propionate de fluticasone. 
Nos résultats démontrèrent qu'à certains niveaux l'inhibiteur IKK-2 a un profil anti-
inflammatoire plus développé en comparaison à celui du fluticasone propionate.  
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CHAPTER I: 
NASAL INFLAMMATORY DISEASES 
___________________________________________________________________________ 
 
Allergic rhinitis and nasal polyposis are both chronic nasal inflammatory diseases. The 
inflammatory response shows many similarities such as elevated IgE, elevated IL-5 and 
eosinophilia. However the magnitude of inflammation is much more prominent in nasal 
polyposis. Current treatment is sometimes unsatisfactory.  
Drugs targeting kinases, have become the focus of a large number of drug discovery programs 
in the pharmaceutical and biotech industry. In laboratory settings, new molecules are 
primarily tested in animals or on cell lines. However, responses in animals or in vitro may 
differ from responses in human tissue. To avoid misleading conclusions, new pharmaceutical 
molecules should be tested in ex vivo models of human disease relevant tissue before testing 
such molecules in clinical settings. 
 
Kinases, important in the signal transduction pathways in allergic rhinitis and nasal polyposis 
have been the target of interest. Mast cells are crucial effector cells in the allergic cascade. 
After the cross-linking of the high affinity IgE receptor (FcRI) they release and produce a 
wide array of mediators important in the early and late phase of allergic rhinitis. 
An early - and late phase model on inferior turbinate tissue and nasal polyp tissue would 
allow us to test these kinds of drugs. Furthermore the usability of nasal polyp tissue versus 
inferior turbinate tissue would be of great importance as polyp tissue is easier to obtain in 
larger quantities. 
 
In this thesis, tissue of both disease identities was used in ex-vivo stimulation models. Two 
kinase inhibitors were tested, namely a Syk inhibitor and an IKK2 inhibitor.  
Syk kinase is positioned upstream of the IgE receptor signal transducing pathway and IKK2 
helps activating the NF-B transcription factor and therefore they may represent important 
targets for the blockage of early- and late phase release of mediators.   
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ALLERGIC RHINITIS 
In the general population in Europe, the prevalence of allergic rhinitis is found to be about 
25%. It ranges from 17% (Italy) to 28,5 % (Belgium)1, 2. The ISAAC study (The International 
Study on Asthma and Allergy in Childhood) demonstrates the prevalence of asthma and 
rhinitis symptoms in children throughout the world. The prevalence of allergic rhinitis varies 
across centres from 0.8% to 14.9% in 6-7 year olds and from 1.4% to 39.7% in 13-14 year 
olds. It is likely that environmental factors are responsible for the major differences among 
countries3, 4. The prevalence of allergic rhinitis is higher in urban than in rural areas5. An 
increase in the prevalence of allergic rhinitis has been observed over the past 40 years of the 
last millennium4, 6, 7. In countries with high prevalence, rates are now plateauing or 
decreasing4.  
Definition 
Allergic rhinitis is clinically defined as a symptomatic disorder of the nose induced after 
allergen exposure by an IgE-mediated inflammation8. Symptoms of allergic rhinitis include 
rhinorrhea, nasal obstruction9, nasal itching and sneezing which are reversible spontaneously 
or with therapy10, 11.  
 
Previously allergic rhinitis was subdivided based on the time of exposure into seasonal, 
perennial and occupational12, 13. Perennial allergic rhinitis is most frequently caused by indoor 
allergens such as house dust mite, molds, insects and animal danders. Seasonal allergic 
rhinitis is related to a wide variety of outdoor allergens such as pollens and molds. This 
classification was not entirely satisfactory f.e. in certain areas pollen are perennial allergens14 
or symptoms of perennial allergens may not be present all year round15, and the majority of 
patients are sensitized to many different allergens and therefore exposed throughout the year. 
In a lot of patients, perennial symptoms are often present and patients experience seasonal 
exacerbations when exposed to pollens or molds11, 16.  
 
In 2001 a major change in the classification of allergic rhinitis was proposed in the ARIA 
(allergic rhinitis and its impact on asthma) document10. Nowadays, allergic rhinitis is 
subdivided into intermittent allergic rhinitis or persistent allergic rhinitis. The severity of 
allergic rhinitis can be classified as “mild” or “moderate/severe” (table 1). 
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Table 1. Classification of allergic rhinitis according to ARIA10 
 
The diagnosis of allergic rhinitis is based upon the concordance between a typical history of 
allergic symptoms and diagnostic tests. Objective tests for the diagnosis of IgE-mediated 
allergy are the skin prick test and the measurement of serum specific IgE with RAST 
(radioallergosorbent test) 17, 18. 
Comorbidities 
Asthma 
The majority of patients with asthma experience rhinitis symptoms, suggesting the concept of 
“one airway disease” 19, 20. The presence of allergic rhinitis commonly exacerbates asthma, 
increasing the risk of asthma attacks, emergency visits and hospitalizations for asthma21. 
However, not all patients with rhinitis have asthma. The prevalence of asthma in patients with 
allergic rhinitis varies from 10% to 40% 19, 22. Patients with moderate/severe persistent 
allergic rhinitis are more likely to suffer from asthma than those with intermittent allergic 
rhinitis and/or a milder form of the disease23. 
Allergic conjunctivitis 
Ocular symptoms occur in a large proportion of patients with rhinitis. Allergic conjunctivitis 
is more common with outdoor allergens than with indoor allergens. In some studies on pollen 
allergy, conjunctivitis is sometimes present in over 75% of patients suffering from rhinitis. 
However, the prevalence of the association between rhinitis and conjunctivitis cannot easily 
-“Intermittent” means that the symptoms are present: 
<4 days a week 
Or for <4 consecutive weeks. 
-“Persistent” means that the symptoms are present: 
More than 4 days a week, 
And for more than 4 consecutive weeks. 
-“Mild” means that none of the following items are present: 
Sleep disturbance, 
Impairment of daily activities, leisure and/or sport, 
Impairment of school or work, 
Symptoms present but not troublesome. 
-“Moderate/severe” means that one or more of the above items are present 
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be defined, because conjunctival symptoms are often considered to be of minor importance 
and are possibly not spontaneously reported by patients. Accordingly, the association between 
rhinitis and conjunctivitis is probably largely underestimated in epidemiologic studies24. 
Rhinosinusitis and nasal polyposis 
It has been speculated that nasal inflammation induced by IgE-mediated mechanisms favours 
the development of acute and/or chronic sinus disease. Sinus involvement has been observed 
by CT-scans in allergic patients25 and total serum IgE correlates with the thickness of sinusal 
mucosa observed on CT-scans26. However, epidemiologic studies are inconclusive and are not 
conclusive to estimate that allergic rhinitis may predispose to the development of 
rhinosinusitis. There are no prospective studies on the incidence of rhinosinusitis in patients 
with and without allergic rhinitis. However, there is a high prevalence of sensitization to 
allergens in patients with acute and chronic rhinosinusitis27. 
Both allergic rhinitis and nasal polyposis are characterized by an inflammatory response that 
shows many similarities, however, until now, no clear data support a role of allergy in nasal 
polyposis. 
 
Fig.:Comorbidities of allergic rhinitis and nasal polyposis. Adapted from ARIA8 and EPO3S28
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Otitis media with effusion (OME)  
In view of the concept of global airway allergy, it may be expected that an allergic 
inflammatory response may also take place in the middle ear. Allergic rhinitis patients have a 
higher risk of Eustachian tube dysfunction than non allergic subjects, particularly during 
childhood29. Eustachian tube dysfunction may lead to OME. The middle-ear fluid of atopic 
patients with OME contains more eosinophils and IL-4 and IL-5 mRNA-positive cells 
compared to nonatopic patients with OME, suggesting a role of allergic inflammation in 
OME30. However, the role of allergic rhinitis in OME is the subject of much controversy31.  
Pathophysiology 
Histomorphologically, the nasal mucosa displays structural alterations in response to the 
allergic inflammation. The epithelium shows thickening and hyperplasia with degeneration. 
Initially there is an increase of goblet cell numbers and later a decrease. Furthermore, in the 
lamina propria, blood vessels are dilated and thickened and glands show multiple changes: 
hyperplasia and distension of acini with secretions, degeneration and obstruction of the acini 
and ducts and periglandular cell infiltration of the superficial glands. In addition, there is 
compression and atrophy of the deeper glands. Furthermore, neo-glandular formation has 
been demonstrated in the allergic nasal mucosa. In addition, infiltration with eosinophilic, 
mononuclear and lymphoid cells are evident 32. 
Allergic rhinitis is classically considered to result from a sustained overproduction of IgE in 
response to common environmental antigens, associated with nasal inflammation of variable 
intensity. When an antigen presenting cell has picked up an antigen, it will present the antigen 
peptide through the MHC complex. In allergic rhinitis naïve T cells differentiate more to Th2 
cells than to Th1 cells after the encounter with this activated antigen presenting cell (priming). 
Cytokines produced by Th2 cells (IL-3, IL-4, IL-5, IL-6, IL-8, IL-13) and a downregulation of 
T-regulatory cell responses drive the B cell to produce IgE and stimulate the recruitment, 
maturation, survival and effector function of accessory cells such as eosinophils, basophils 
and mast cells 33. IgE is produced in the local lymphoid tissues and locally in the nasal 
mucosa34, 35. Persistent IgE synthesis takes place in the nasal mucosa during and just after the 
pollen season36. Allergens drive class switching to IgE transcripts in the nasal mucosa in 
allergic rhinitis37.  
 
Early/immediate allergic response. Within minutes of inhalation of allergen in sensitized 
subjects, deposited allergens are recognized by allergen specific IgE antibody and this 
19
Chapter I - Nasal inflammatory diseases  
complex becomes fixed to the IgE receptor (FcRI). Crosslinking of the receptor bound to 
mast cells and basophils, causes degranulation and release of preformed mediators, such as 
histamine and tryptase, and the rapid de novo generation of mediators such as leukotrienes C4, 
D4 and E4 and prostaglandin D238. Mediators cause plasma leakage from blood vessels and 
dilation of arteriovenous anastomoses, with consequent oedema, pooling of blood in 
cavernous sinusoids and occlusion of nasal passages. Furthermore secretion of mucus from 
glandular and globet cells is stimulated. Histamine provokes itching, rhinorrhea and sneezing, 
whereas other mediators are more responsible for nasal congestion. Stimulation of sensory 
nerves results in the perception of nasal congestion and itching and may provoke systemic 
reflexes such as sneezing39. 
Late phase response. Mediators and cytokines released during the early phase set off a 
cascade of events over the following 4 to 8 hours that lead to an inflammatory response called 
the late response. Symptoms are similar to those of the immediate reaction, but nasal 
congestion is more prominent. The expression of adhesion molecules such as E-selectin and 
VCAM-1 is promoted and these give adherence of circulating leukocytes to endothelial cells. 
Mainly eosinophils but also neutrophils, basophils, Th2 lymphocytes and macrophages 
infiltrate the lamina propria of the nasal mucosa39, 40. These cells become activated and release 
more mediators which in turn activate more proinflammatory reactions. 
 
During the pollen season there is an increase in various inflammatory cells, correlating with 
severity of symptoms41. Immunohistochemical staining of nasal biopsies with antibodies 
against mast cell tryptase shows an increase in mast cells within the airway epithelium and 
submucosa in both intermittent and persistent allergic rhinitis when compared to biopsy 
findings in non-atopic subjects42, 43, 44, 45. Epithelial mast cells are in an activated state in 
symptomatic allergic rhinitis with evidence of degranulation on electron microscopy46 and 
with elevated levels of histamine, leukotrienes and tryptase in nasal lavage fluid47, 48. 
Eosinophils are found in the mucosa between epithelial cells, in the submucosa and in nasal 
secretions, and they are present especially in the late-phase allergic response42. They have the 
capacity to produce cytotoxic proteins such as major basic protein, eosinophil peroxidase, 
eosinophil-derived neurotoxin and ECP and are proposed to cause desquamation of the 
airways in vivo. In nasal secretion of rhinitis patients increased ECP is found49. 
Significantly more basophils are found in nasal allergic mucosa and are shown to increase in 
asymptomatic intermittent rhinitis patients following nasal allergen challenge50. Moreover an 
increase in circulating basophils is observed in rhinitis51.  
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An increase in the T-lymphocyte cell population has been described in both intermittent and 
persistent allergic rhinitis. Furthermore, following nasal allergen challenge, an increase in IL-
4, IL-5, and GM-CSF mRNA positive cells has been described in association with mucosal 
eosinophilia, which is consistent with Th2-lymphocyte activation52. Moreover, the role of 
Treg cells in controlling allergic diseases became apparent. In nasal tissue of allergic rhinitis 
patients, a reduced number of FOXP3-positive cells is reported compared to controls53. 
Also Langerhans cells, as well as other dendritic cells, are found in the nasal mucosa. They 
form a network of antigen presenting cells, especially in the epithelial surface. Dendritic cell 
recruitment to the nasal mucosa has been observed during natural seasonal and allergen 
provocation54, 55.  
Treatment 
Topical corticosteroids and oral antihistamines are currently the two most important groups to 
treat allergic rhinitis. The principle of pharmacological treatment is a stepwise approach 
according to the severity and duration. In resistant patients, the effects of allergenspecific 
immunotherapy can be both complementary and synergistic but careful patient selection is 
absolutely crucial to its success. 
Allergen avoidance 
The 2008 ARIA guidelines have reported that there is a lack for the effectiveness of the 
avoidance of house dust mites or pet animal dander8. 
However, for occupational allergic rhinitis strict avoidance of offending allergens is the safest 
and most effective treatment56. 
Oral antihistamines 
H1-blockers or H1-antihistamines are drugs with blocking activity at the H1 histamine 
receptor level. Most of the new oral H1-antihistamines have a fast onset of action (20 minutes 
to 2 hours) and duration of effect that lasts up to 24 hours. They are effective in the treatment 
of rhinorrhea, sneezing, nasal itching and eye symptoms. They are usually less effective 
against nasal obstruction because other mediators, and histamine acting through the H3 
receptor, impact this symptom57. 
First-generation antihistamines, which have been used since the early 1940s, have some side 
effects such as sedation, memory impairment and psychomotor dysfunction. In contrast, 
second-generation antihistamines penetrate the blood-brain barrier far less than first-
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generation antihistamines, and consequently have fewer side effects on the central nervous 
system58. Moreover, in addition to their antagonistic action on histamine receptors, 
antihistamines possess potent anti-inflammatory properties59.Therefore, the use of second-
generation antihistamines is recommended8. 
Intranasal corticosteroids 
Intranasal corticosteroids inhibit both early and late reactions and reduce IgE production and 
eosinophilia by inhibiting the secretion of cytokines including IL-4, IL-5 and IL-13. They are 
effective in all allergic rhinitis symptoms, especially nasal obstruction and eye symptoms60. 
The therapeutic effect of intranasal corticosteroids is encountered 7 hours after administration 
and reaches the maximal level after 2 weeks61. For a better choice of topical steroids, their 
pharmacological characteristics should be considered. Most of the different drugs have similar 
clinical effects, but their systemic absorption is different. Mometasone furoate (Nasonex) and 
fluticasone propionate (Flixonase aqua) have very low absorption rates (<0.1% and <2%) and 
are considered safe for children62, 63. 
Leukotriene receptor antagonists (LTRAs) 
In 2008 ARIA guidelines re-evaluated the role of LTRAs and it was recommended that they 
may be used in all types of severity. Montelukast (Singulair) (LTRA) is effective in reducing 
nasal and eye symptoms in patients with seasonal allergic rhinitis and improves nasal 
obstruction comparable to loratadine (antihistamine). The additive or synergic effect of 
montelukast and loratadine is controversial64, 65. When montelukast and cetirizine were 
administered 6 weeks before the pollen season, the exacerbation of seasonal allergic rhinitis 
symptoms was effectively prevented66. The additive effect of LTRAs and antihistamines 
requires more investigations. Up to now, the pharmacological effects of LTRAs are estimated 
to be similar to those of antihistamines but less than those of intranasal corticosteroids in 
patients with seasonal allergic rhinitis8. 
Decongestants 
Decongestant drugs cause vasoconstriction by their action on -adrenergic receptors, and may 
be administered intranasally or orally. In the short term, these agents are effective in the 
treatment of nasal obstruction in allergic rhinitis. However, these agents do not improve other 
symptoms of rhinitis, such as nasal itching, sneezing or rhinorrhea. A prolonged use may lead 
to rebound swelling of the nasal mucosa (rhinitis medicamentosa). 
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Anti-IgE antibody 
Omalizumab, an anti-IgE recombinant humanized monoclonal antibody, interferes with the 
interactions between mast cells/eosinophils and IgE by binding to free IgE and hence lowers 
serum free IgE. It also suppresses inflammatory reactions in blood or nasal mucosa67, and 
suppresses the expression of FcRI located on the surface of mast cells or eosinophils68. 
While anti-IgE antibody therapy appears to be helpful in severe asthma, it is controversial 
whether anti-IgE therapy is suitable as a treatment option for allergic rhinitis, due to 
anaphylactic risk and high costs. 
Topical anticholinergics 
Parasympatic stimulation of the nasal glands results in vasodilatation of the blood vessels that 
supply them and in an associated watery secretion. The muscarinic receptors can be blocked 
by the anticholinergic drug ipratropium bromide, which is available as a nasal spray. Its use 
can be combined with intranasal corticosteroids or antihistamines when rhinorrhea is the 
predominant symptom. Ipratropium bromide may also be of specific interest for use in elderly 
patients with isolated rhinorrhea, or in patients with rhinorrhea secondary to contact with cold 
air.  
Immunotherapy 
Allergen-specific immunotherapy, performed under controlled conditions with immediate 
access to resuscitative equipment, has a prominent role in the treatment of severely 
symptomatic patients with allergic rhinitis who have failed to respond to conventional 
treatment. Extracts of offending allergens are injected subcutaneously with increasing doses 
until a maintenance dose is reached. Recently, sublingual immunotherapy starts to replace 
subcutaneous immunotherapy. Regulation of antigen-specific responses (an increase in the 
IgG4/IgE ratio), inhibition of recruitment/activation of inflammatory cells, shift of Th2 to Th1 
responses and activation of regulatory T cells are the main mechanisms of immunotherapy. 
 
NASAL POLYPOSIS 
The prevalence of nasal polyposis varies between 1% and 4% of the general population69, 70. 
In nasal polyposis the male: female ratio is 2: 1 and it is more likely to occur in elderly 
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patients69. The average onset is approximately at 42 years old71. Under the age of 20, nasal 
polyps are uncommon and are more related to cystic fibrosis72, 73. 
Definition 
According to the European position paper on rhinosinusitis(EPO3S), nasal polyposis is a 
disease which is included in the current clinical definition of  rhinosinusitis. Rhinosinusitis is 
defined as an inflammation of the nose and the paranasal sinuses characterized by two or 
more symptoms including nasal blockage, anterior or posterior nasal drip, facial pain or 
pressure, and reduction in or loss of smell. Furthermore, together with the symptoms, there 
must be endoscopic signs and/or changes identifiable using computed tomography (CT). 
Endoscopic signs include the presence of polyps, mucopurulent discharge from the middle 
meatus and/or oedema or mucosal obstruction primarily in the middle meatus. The CT 
changes are mucosal swelling within the ostiomeatal complex and/or sinuses. Severity of 
sinus disease can be divided in mild, moderate or severe, based on a severity visual analogue 
scale. Based upon duration of symptoms there is the difference between acute rhinosinusitis, 
when symptoms resolve completely within 12 weeks, and chronic rhinosinusitis, when 
symptoms last longer than 12 weeks. For general practice, however, diagnostic tools are 
limited to symptoms.  
For research purposes nasal polyposis is considered as a subgroup of chronic rhinosinusitis 
and the differentiation must be based upon endoscopic evaluation with presence of polyps or 
not28, 74. 
To determine the severity of the disease a score is given from 0 to 375 or from 0 to 
476depending on the endoscopic size of the polyps. The scoring system from 0 to 4 has proved 
to be the most reliable77.To examine the anatomical extent of nasal polyps, a CT scan is 
performed. Here the grading score of Lund Mackay is used and recommended77. Nor the 
endoscopic size78, nor the CT scores79 correlate well with patient’s symptom scores. 
Comorbidities 
Asthma 
In asthma, 7% of patients have nasal polyposis80. The proportion is higher in patients with 
nonatopic asthma (13%) than in those with atopic asthma (5%)81. Late-onset asthma is 
associated with development of nasal polyposis in 10-15%80. 
 In patients with nasal polyposis, asthma is present in 20 to 70%82, 83 and 15% have aspirin-
intolerance84. In approximately 69% of patients with both asthma and nasal polyposis, asthma 
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is the first disease to develop, and nasal polyposis takes between 9 and 13 years to be 
diagnosed. In only 10% of patients with both asthma and nasal polyposis both diseases do 
develop simultaneously, and in the remaining patients polyps develop first, followed 2-12 
years later by asthma81. In nasal polyps the male: female ratio is 2: 1. Women with nasal 
polyposis, however, are 1.6 times more likely to be asthmatic and 2.7 times more likely to 
have allergic rhinitis than are men85. 
Aspirin-intolerance 
The triad of asthma, nasal polyps and intolerance to aspirin and aspirin-like medications is 
known as the Samter’s triad86. Alterations in arachidonic acid metabolism have been 
suggested as one of the main factors driving to aspirin-intolerance87-89. 
Of patients with aspirin-intolerance, 36-96% have nasal polyps and aspirin-intolerance is 
present in 5-10% of asthmatic patients86, 87. 
Patients with asthma, nasal polyposis and aspirin sensitivity are usually nonatopic and the 
prevalence increases in those older than 40 years. When parents have asthma, nasal polyposis 
and aspirin sensitivity, their children more commonly suffer from nasal polyposis and 
rhinosinusitis than do control children90. Of 500 patients with aspirin-induced asthma , nasal 
polyposis was diagnosed in 62% of them87. 
Allergy 
Due to similarities in cytokine measurements in allergic rhinitis patients and nasal polyposis 
(elevated IgE, elevated IL-5, eosinophilia), a link was postulated between allergy and nasal 
polyposis. However, only 2.8% of allergic rhinitis patients have nasal polyposis while nasal 
polyps are found in 5.2% in non-allergic rhinitis patients80. Furthermore, allergen exposure in 
nasal polyp patients with a positive skin-prick test to ragweed, does not induce elevation of 
inflammatory parameters91 and moreover, local and specific IgE in nasal polyps correlates 
with local eosinophilic inflammation but does not correlate with skin prick test results92. 
Pathophysiology  
Nasal polyps appear as grape-like structures in the upper nasal cavity and are found in the 
middle nasal meatus or arise from the middle turbinates. Histomorphologically, the epithelium 
is mostly respiratory ciliary pseudo-stratified epithelium with less ciliated and more globet 
cells compared to normal healthy tissue93. Common features in bilateral polyps are epithelial 
damage, a thickened basement membrane, loose connective tissue with a reduced number of 
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blood vessels and glandular structures and no nervous structures94. In the stroma of nasal 
polyps often edema and pseudocystic formations are found. Albumine and other plasma 
proteins have been found within those pseudocysts. Furthermore, in patients from Western 
countries more than 70% of polyps exhibit abundant eosinophils, and these are located around 
the vessels, glands and directly beneath the mucosal epithelium95. The eosinophils are 
activated and are believed to play a central role in polyp formation and growth of nasal 
polyps96. Other inflammatory cells seen in nasal polyps are lymphocytes and mast cells. Mast 
cells can be detected in the epithelium as well as in the stroma of nasal polyps. It is well 
described that the majority of degranulated mast cells are localized in the deep stroma of nasal 
polyps 97, 98. In most nasal polyps follicular structures characterized by B and T cells, and 
lymphoid accumulations with diffuse plasma cell infiltration have been found, suggesting a 
local production of immunoglobulines99.  
 
An increased production of chemokines/cytokines have been found in nasal polyps. Increased 
IL-5, RANTES and eotaxin induces eosinophil chemotaxis, migration, activation and 
prolonged survival 96, 100-102. Regulation of eosinophils in polyps is partially understood; in-
vitro treatment of eosinophil infiltrated polyp tissue with neutralizing anti-IL-5 monoclonal 
antibody resulted in eosinophil apoptosis and decreased tissue eosinophilia103 and anti-IL-5 
treatment in vivo resulted in reduction of eosinophils and ECP in serum and nasal 
secretions104.  Furthermore, increased concentrations of eosinophilic toxins like ECP and 
MBP are found in nasal polyps and the eosinophilic marker eotaxin is also more often found 
in nasal polyps compared to controls105. IL-5 expression has been found to correlate with ECP 
in polyp tissue suggesting its autocrine role in the activation of eosinophils92.  
This T-cell activation with Th-2 polarisation pattern and eosinophilic inflammation, goes 
together with a decreased expression of FOXP3 (transcription factor for T regulatory cells), 
reflecting a deficiency or dysfunction of Treg cells in an often persistent, severely inflamed 
sinus disease. In line with low FOXP3 expression, low levels of TGF-1 protein expression 
and an upregulation of transcription signals for Th1 (T-bet) and Th2 (GATA-3) 
subpopulations were found, pointing to a defective suppression106. 
Next to the high IL-5, another typical finding in nasal polyp tissue is the high local total 
amount of IgE. It mostly doesn’t correlate with the serum IgE92. Furthermore polyclonal IgE 
is present in nasal polyp homogenates and again it doesn’t correlate with specific serum IgE 
or results of skin prick test. This polyclonal type is associated with high IgE concentrations 
and specific IgE antibodies against S. aureus enterotoxins99. Not only high concentrations of 
26
Chapter I - Nasal inflammatory diseases  
IgE can be found in nasal polyp homogenates, but also significantly higher IgA, total IgG and 
IgG subclasses are found compared to controls. This observation could not be found in serum. 
Furthermore, naïve B cells and plasma cells were significantly higher in nasal polyp tissue, 
suggesting a local production of immunoglobulins107.  
Another finding in nasal polyp tissue is the increase of leukotriene C4 synthase mRNA, 5-
lipoxygenase mRNA and proinflammatory cysteinyl leukotrienes and the decrease of others 
such as cyclo-oxygenase 2 mRNA and prostaglandin E2 in parallel with the severity of 
disease89. Prostaglandin E2 can be considered an anti-inflammatory metabolite as it may 
induce FOXP3 expression and thus influence the formation of T-regulatory cells108. 
Consistent with the oedema formation and extracellular matrix destruction in nasal polyps, an 
upregulation of metalloproteinases (MMP)-7 and (MMP)-9, but not of the tissue inhibitor of 
metalloproteases (TIMP)-1 has been described109, which is in line with a lack of upregulation 
of TGF-1, a TIMP-1 inducing and pro-fibrotic growth factor105. Additionally a low number 
of pSmad-2 positive cells, a decreased expression of TGF- R II and a lack of collagen was 
found in nasal polyps, all indicating a low level of TGF- signalling110. 
In general, chronic rhinosinusitis with nasal polyps is characterized by a predominant Th2-
biased eosinophilic inflammation with high levels of IL-5, ECP and eotaxin; high levels of 
local IgE; and low levels of TGF-1 and they consist of albumin accumulation and edema 
formation within the extracellular matrix (pseudocyst formation). 
All these studies were mainly performed on European and US nasal polyps. Recently, a 
difference has been demonstrated in inflammatory cells and cytokine pattern between 
Caucasian and Asian nasal polyps. Asian polyps demonstrated more Th1 and Th17 signals, 
including T-bet (transcription factor for Th1 cells) expression and IFN- protein formation, 
and IL-17 and the related cytokines IL-1 and IL-6 protein synthesis in tissue 
homogenates111. This new view on the type and role of inflammation in airway disease needs 
to be elaborated. 
S. aureus superantigens as disease modifiers 
Enterotoxins derived from Staphylococcus aureus, a gram positive bacterium, have been 
implicated in the pathophysiology of nasal polyps as disease-modifying factors. These S. 
aureus -derived enterotoxins (SAEs) are called “superantigens” as they have the ability to 
crosslink the class II major histocomptability complex of antigen-presenting cells and the T-
cell receptor (TCR) β-chain variable regions. This crosslinking takes place outside the 
conventional antigen-binding grove. This may lead to the stimulation of up to 20-25% of the 
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T-cell population in a non-specific way, compared with stimulation of only about 0.1% via 
the conventional allergen-specific way112. Once activated, T-cells may produce interleukins 
including IL-4, IL-5, IL-13, eotaxin and many others, which may lead to an eosinophilic 
inflammation and local IgE-production. Specific IgE against SAEs is found more frequently 
in nasal polyp tissue versus controls and correlates with higher levels of IL-5, eotaxin, and 
ECP92. Moreover, an increased number of T cells expressing the TCR -chain variable region, 
known to be induced by microbial superantigens, was detected in NP and correlated with the 
presence of IgE against SAEs113.  Furthermore, in polyp homogenates positive for sIgE 
against SAEs, a greater fraction of IgG4 was observed and this correlated with IgE and the 
number of plasma cells107. Additionally, in polyp homogenates positive for sIgE against 
SAEs, production of leukotrienes and lipoxin A4 is upregulated114. 
Colonization with S. aureus was present in more than 60% of patients with polyps, with rates 
as high as 87% in the subgroup with asthma and aspirin sensitivity, which were significantly 
higher than in control individuals and patients with chronic rhinosinusitis without nasal 
polyps (33% and 27%, respectively)115. However, the presence of S. aureus in the submucosa 
of nasal tissue did not correlate with the amplification of the Th2-related inflammation 
typically found in nasal polyps, but this reaction is dependent on the formation of specific IgE 
against SAEs116. In nasal polyps versus controls, similar percentages of enterotoxin genes are 
present; however, in nasal polyps a higher number of strains belonged to agr I or II, which are 
associated with strains causing enterotoxin-mediated disease117.  
Treatment 
The primary goal of treatment for patients with nasal polyposis is the relief of symptoms such 
as nasal blockage, hyposmia, rhinorrhea or postnasal drip. Oral and topical corticosteroids 
represent the major treatment strategies, followed by surgical interventions. However, 
recurrences are frequent regardless of treatment, making a combination of repeated surgical 
interventions and a long-term drug treatment necessary118. 
Corticosteroids 
The biological action of glucocorticoids is mediated through activation of intracellular 
glucocorticoid receptors (GR) expressed in many tissues and cells119. Two human isoforms of 
the receptor have been identified, GR and GR. Upon hormone binding, GR enhances 
anti-inflammatory or represses pro-inflammatory gene transcription. This is mediated by 
protein-protein interactions between GR and transcription factors such as AP-1 and NF-B119. 
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Topical corticosteroids sprays have a documented effect on the size of bilateral nasal polyps 
and also on symptoms associated with nasal polyposis such as nasal blockage, secretion and 
sneezing but the effect on the sense of smell is not high28. Several studies underline the effect 
of topical corticosteroids to reduce nasal polyp size, reduce complaints of nasal obstruction 
and increase nasal airflow120-122. Efficacy of treatment of nasal polyps with topical 
glucocorticosteroids is partly associated with their ability to reduce eosinophil viability and 
activation123, 124, and to reduce the secretion of chemotactic cytokines124, 125. Intranasal 
corticosteroid treatment postoperative gives long-term improvement in nasal symptoms and 
reduces polyp recurrence126. Topical application of corticosteroids reduces side effects; 
however nasal sprays cannot reach the middle meatus where polyps originate. Adverse effects 
with topical corticosteroids are rare, but may consist of dry nose, crusting and eventually mild 
bleeding.  
Based on clinical experience systemic corticosteroids remain a cornerstone for the treatment 
of nasal polyps and are indicated to initiate or enforce local treatment, mainly as a 2 to 3 
weeks’ course. According to experts opinion such treatment may be given up to four times a 
year if no contra-indications are present or no side-effects occur127. In a Cochrane review of 
2007128 only one small randomized controlled trial was found that suggests a short-term effect 
of oral steroids in patients with multiple nasal polyps129. In a more recent, double-blind 
placebo controlled multicenter study nasal polyposis patients were treated with placebo or 
methylprednisolone in decreasing doses or doxycycline, and patients were followed for 12 
weeks. Until month 2 the methylprednisolone group had a significant reduction in polyp 
score, with a maximal reduction in polyp size after 2 weeks. This group reported decrease in 
nasal congestion, post-nasal drip symptoms and better smell after a few weeks. No effect on 
rhinorrhea was described. Methylprednisolone significantly reduced levels of ECP, IL5 and 
IgE in nasal secretions130. 
Antibiotics 
As a new approach, antibiotics with anti-inflammatory effect are being used to treat nasal 
polyposis. Several studies have shown the effect of macrolide antibiotics in patients leading to 
a reduction in polyp size together with a decrease of IL-8 in nasal lavage131, 132. Long term 
treatment with these drugs may induce bacterial resistance, which may limit this approach. 
Placebo-controlled studies with macrolides in nasal polyps are clearly needed before final 
conclusions.  
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As S. aureus enterotoxins may be considered as disease modifiers in nasal polyposis, in a 
double-blind placebo controlled multicenter study nasal polyposis patients were treated with 
placebo, or methylprednisolone in decreasing doses, or doxycycline, and patients were 
followed for 12 weeks. Doxycycline was used because of its antibacterial activity against S. 
aureus as well as its anti-inflammatory properties. It significantly reduced polyp size, starting 
at week 2, and this effect remained for up to 12 weeks after dosing. Furthermore it reduced 
postnasal drip symptom scores and induced a reduction in rhinorrhea. It also reduced levels of 
myeloperoxidase, ECP an MMP9 in nasal secretions130. 
Anti-IL-5 
IL-5 concentrations are increased in nasal polyps and activate and prolong survival of 
eosinophils. One double-blind placebo-controlled study showed that administration of a 
humanized anti-IL-5 is a safe and well-tolerated therapy. However, only 50% of the patients 
showed a clinical response with reduction of polyp size. Subgroup analysis demonstrated that 
high local IL-5 concentrations in nasal secretions predicted the positive response104. 
Surgery 
Functional endoscopic sinus surgery (FESS) is now widely accepted as the surgical treatment 
of nasal polyposis. Surgery should be considered only after appropriate pharmaceutical 
therapy. However, nasal polyposis is a chronic inflammatory disease with a high rate of 
recurrence. The recurrence rate after surgery is linked to previous surgery, asthma and 
allergy133. In nasal polyp patients with co-morbid asthma and aspirin sensitivity, surgery 
improves asthma symptoms for relatively long periods of time. Especially in the first year 
after surgery emergency department visits, hospitalizations and asthma attacks decreased in 
about 90% of the patients134. 
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CHAPTER II: 
HUMAN MAST CELLS: ORCHESTRATORS OF NASAL 
INFLAMMATORY DISEASES? 
___________________________________________________________________________ 
From bone marrow to nasal tissue 
It has been more than a century (1878) since the discovery of mast cells whom Paul Ehrlich is 
credited for1. Since then, subsequent developments have started about the immune response, 
immunoglobuline E and the function of mast cells in various pathological states. 
 
In vivo, mast cells may only be identified when they are totally matured in tissue and then 
consequently express their characteristic granules and high-affinity receptor for IgE (FcεRI). 
Human mast cells are believed to derive from pluripotential CD34+c-kit+CD13+ progenitors 
2, 3 . These progenitors arise from the uncommitted hematopoietic stem cells in bone marrow4 
and are present in bone marrow, peripheral blood, human fetal liver5 and cord blood. The 
interactions between the membrane receptor c-kit and its ligand, stem cell factor (SCF), and 
the subsequent signalling that follows, are crucial for the growth and the development of mast 
cells. SCF is expressed in endothelial cells, fibroblast and other stromal cells6. SCF has 
multiple biological effects on mast cells, including growth, differentiation and homing, 
prolonging viability, inducing mast cells hyperplasia, and enhancing mediator production7, 8. 
Furthermore, IL-6, eotaxin, and nerve growth factor (NGF) enhance mast cell development 
from hematopoietic stem cells9, 10  
After tissue localisation, mast cells can undergo further differentiation into distinct subsets. In 
terms of granule constituents, human mast cells have been divided into three phenotypes: 
those only positive for tryptase (MCT), those positive for tryptase and chymase (MCTC) and 
those only positive for chymase (MCC). All three subtypes are present in human nasal tissue11. 
MCTC is more present in connective tissue, whether MCT is mainly localized into mucosal 
surfaces, often in close proximity to Th2 cells. This subset usually is noticed in increased 
numbers infiltrating the mucosa in patients suffering from allergic disease12. 
In vitro, it is possible to grow human mast cells from bone marrow, peripheral blood 
mononuclear cells and cord blood mononuclear cells13, 14. 
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Morphological characteristics of human mast cells 
Mature human mast cells are large, mononuclear cells filled with membrane-bound secretory 
granules. The nucleus has a partially condensed chromatin pattern. The secretory granules 
exhibit metachromasia when stained with toluidine blue. Other cytoplasmatic features include 
small Golgi structures and different amounts of lipid bodies. They extrude membrane-free 
granules either into newly formed degranulation channels in the cytoplasm or individually 
through pores in the plasma membrane to the exterior environment, when appropriately 
stimulated15.  
Activators and mediators  
In a typical allergic reaction, antigen/ allergen crosslinks two IgE molecules occupying FcRI, 
resulting in a cascade of molecular events (see next chapter), and leading to degranulation and 
elaboration of mediators16. Furthermore, a variety of stimuli can activate and degranulate mast 
cells: opiates, complement factors C3a and C5a, neuropeptides (substance P, vasoactive 
intestinal peptide, calcitonin gene-related protein), histamine releasing factors (a 
heterogeneous group of cytokines eg. IL-1, IL-3, IL-8, GM-CSF, TNF-)17, chemokines, 
bacteria, parasites or changes in osmolality. Consequently a lot of membrane receptors are 
present on human mast cells. They express FcRI, FcRI, and the c-kit receptor18. They also 
express Toll-like receptors (TLR2-7 and TLR9)19 and CysLTR1 and CysLTR220. Mast cells 
express at least four chemokine receptors (CCR3, CXCR1, CXCR3 and CXCR4)21 and 
cultured mast cells express low levels of IL-4R, IL-5R and integrins and P-selectin ligand 
to bind to adhesion molecules6. Furthermore, they express the histamine H4 receptor22. 
Mast cells produce a wide array of mediators and cell signalling molecules, and this variety 
may account for the unique features of the mast cell in the immune system. Human mast cells 
synthesize histamine, which is stored in secretory granules as a preformed mediator. These 
granules also contain a variety of proteolytic enzymes ( and  tryptase, chymase, 
carboxypeptidase A and cathepsin G) and proteoglycans (heparin and chondroitin sulphate 
E)23. Activation of mast cells leads to the synthesis of PGD2 and cysLTs (LTB4, LTC4, LTD4 
and LTE4). There are wide varieties in the cysLTs production amount among different human 
tissue mast cells suggesting that this biochemical property is modulated by tissue specific 
factors. In contrast, the apparent consistency in PGD2 production of all human mast cells 
suggests that this is an innate characteristic. After allergenic stimulation, mast cells 
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immediately release histamine, which is preformed. Leukotrienes and prostaglandins need to 
be metabolized and are released about 10 minutes later.  
Furthermore they are a major source of a wide spectrum of cytokines (IL-3, IL-5, IL-6, IL-13, 
IL-16, IL-18, IL-25, TGF-, GM-CSF, TNF-) and chemokines (IL-8, MIP-1, MCP1,…). 
Interestingly, SCF, the principal growth, differentiating and chemotactic factor for human 
mast cells is present and released by mast cells, which may represent an autocrine factor that 
sustains mast cell hyperplasia in allergic diseases24. 
 
 
Mast cells in allergic rhinitis 
Immunohistochemical staining of nasal biopsies with monoclonal antibodies directed against 
mast cell tryptase shows an increase in mast cells in both intermittent and persistent allergic 
rhinitis as compared to biopsy findings in non-atopic  and non-rhinitis subjects25, 26. In 
symptomatic allergic rhinitis epithelial mast cells are in an activated state with evidence of 
degranulation27. Morphologically, mast cells in the nasal epithelium and the superficial lamina 
propria resemble MCT and those in the deep lamina propria resemble MCTC28. Several mast 
cell derived mediators like histamine29, PGD229, cysLTs30 and tryptase31 are elevated in nasal 
lavage fluid after allergen challenge and during the season in naturally occurring rhinitis32. 
It is well known that mast cell numbers (MCT) are increased in the epithelium of the allergic 
nasal mucosa33. The mechanism for this accumulation is not completely clear. It has been 
suggested that the accumulation of mast cells in nasal epithelium was due to the cytokine 
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SCF, produced from nasal epithelial cells34. In human allergic nasal mucosa CD34+, c-kit 
receptor+, tryptase negative and IgE negative cells were detected and were presumed to be 
mast cell progenitor cells and may contribute to the increase of fully matured mast cells in the 
epithelium and subepithelial layer of allergic nasal mucosa35. 
Not only Th2 cells can induce IgE synthesis in B cells but also mast cells can. Nasal mast 
cells from perennial allergic rhinitis patients express significantly greater levels of 
FcepsilonRI and CD40L compared to controls and after allergen challenge they can induce 
IgE synthesis in B cells36. 
Mast cells in nasal polyps 
Literature reports show contradictory findings concerning the number of mast cells in nasal 
polyps; it has been described that the number of epithelial mast cells in nasal polyps is 
elevated compared to controls37, 38, or that there is no difference in the number of epithelial 
mast cells compared to controls39-41. The number of tryptase positive cells is not significantly 
different between atopic nasal polyps and non atopic nasal polyps, demonstrating that the 
presence of atopy does not determine the type of extent of mast cell infiltration in nasal 
polyps42. There is a significant expression of SCF mRNA and protein in cultured nasal polyp 
epithelial cells and fibroblasts43. Furthermore, the number of polypectomies correlate with 
expression of SCF mRNA, SCF protein in nasal polyp epithelial cell supernatants and the 
density of mast cells in the epithelial layer and the stromal layer44. 
It is well described that mast cells in nasal polyps are mostly located in the stroma and are 
more degranulated compared to inferior turbinate mast cells45, 46. Furthermore, stromal mast 
cells of dispersed nasal polyp tissue release higher amounts of histamine after anti-IgE 
stimulation compared to epithelial mast cells of the same tissue47. This could underline the 
heterogeneity of mast cells in different tissue localizations, and could point to a more 
activated status of polyp versus turbinate mast cells, and a higher sensitivity to external 
triggers. Levels of mast cell-derived mediators such as histamine and tryptase in nasal fluids 
from patients with nasal polyps are significantly higher than those observed in patients 
without nasal polyps48.  
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CHAPTER III: 
 NEW THERAPIES IN INFLAMMATORY DISEASES: KINASE 
INHIBITORS 
________________________________________________________ 
 
The discovery of novel drugs targeting kinases has become the focus of a large number of 
drug discovery programs in the pharmaceutical and biotech industry.  
Kinases are an important class of intracellular enzymes that play a critical role in signal 
transduction pathways controlling a variety of cellular functions. The role of a protein kinase 
in the signal transduction is to transfer the terminal phosphate group of ATP to the hydroxyl 
group of a serine, threonine or tyrosine residue on the target protein, leading to the activation 
of the substrate for its role in the next step of the signalling cascade1. The substrate is often 
another kinase or a transcription factor.  
The protein kinases are classified as serine/threonine or tyrosine substrate kinases based on 
the receiving amino acid of their substrates. Analysis of the human genome showed that there 
are 518 protein kinases, of which only 90 are tyrosine kinases, and these include 58 receptor 
tyrosine kinases2.  
A large majority of kinase inhibitors are designed to inhibit the enzyme, by binding them at or 
near the ATP-binding site. An inhibitor of one kinase is often found to inhibit other 
structurally related or unrelated kinases. Therefore, extensive profiling is necessary.  
  
In the present century, protein kinases, especially the tyrosine protein kinases, have become 
prime targets for cancer intervention. Until the late 1990s, anti-cancer drugs were directed 
towards metabolic enzymes (e.g. methotrexate), to DNA (e.g. cisplatin), to hormonal 
signalling pathways (via nuclear hormone receptors for breast (e.g. tamoxifen) and prostate 
cancer (e.g. flutamide)),... Nowadays, as an anti-cancer therapy, always in combination with 
other drugs,  there are 10 protein kinase inhibitors that are approved and in clinical use, as 
well as many more compounds in clinical trials1. 
Protein kinases are also targets for treatment of inflammatory and autoimmune diseases. 
Progress has been made in these areas and some drugs are in different phases of clinical trials 
(phase I/II)3, but to our knowledge none of these inibitors have reached the clinical stage of 
drug development, possibly because of the complexity of the signalling pathways that 
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involves a lot off cross-talk between pathways. One of the reasons for this lack of success for 
the treatment of patients with inflammation or autoimmune disorders, has been the high 
hurdle for safety required for the chronic treatment of patients whose life expectancy is 
usually significantly longer than that of cancer patients4. 
A large number of kinases from different signal transduction pathways have been the targets 
of interest for the treatment of inflammatory disorders. Examples of drugs targeting such 
kinases are inhibitors of Syk (spleen tyrosine kinase), IKK-2 (IB kinase 2), MAP (mitogen-
activated protein kinases), Lck (lymphocyte-specific kinase), JAK3 (Janus kinase 3), …3, 4  
A majority of kinase inhibitors have inhibitory activity for one kinase and are found to be 
potent inhibitors of other kinases.  
 
The kinase inhibitors we tested are a Syk inhibitor and an IKK-2 inhibitor and they were 
profiled for a particular kinase. Extensive profiling has already been done in inflammatory 
and autoimmune disorders such as asthma and rheumatic arthritis, less research is done in the 
field of allergic rhinitis. No studies were published yet about the efficacy in treating nasal 
polyposis. Practically all studies used animal models so far.  
SYK INHIBITION 
Spleen tyrosine kinase (Syk) is a cytosolic protein tyrosine kinase that plays a crucial role in 
the IgE (FcRI) and IgG (Fc) receptor-mediated signalling in mast cells5, 6 and basophils7. 
Mast cells are multifunctional effector cells of the immune system and they play a crucial role 
in the allergic response.  
The IgE/ allergen –mediated stimulation through the cross-linking of the high-affinity 
receptor for IgE (FcRI) remains a very important step in the activation of the mast cell. The 
FcRI expressed on mast cells and basophils is a tetrameric receptor comprised of the IgE-
binding  chain, the signal-amplifying  chain8 and the two signal transducing  chains9. 
The transmission of the signals is dependent on the specific sequence of the immunoreceptor 
tyrosine-based activation motif (ITAM) present on the  and  chains. Following subsequent 
allergen exposure, receptor crosslinking results in the recruitment and the activation of 
cytoplasmatic kinase Lyn. Lyn causes tyrosine phosphorylation of ITAM in the cytoplasmatic 
domains of - and -chains. Phosphorylated ITAM in the -chains serve as binding sites for 
Syk SH2 domains. As a result of its binding to ITAM, Syk becomes activated10-13. Activated 
Syk regulates the phosphorylation of a host of substrates that form signalling complexes, 
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which are necessary for downstream signal transductions that result in mediator release and 
production. It phosphorylates the membrane proximal adaptor linker for activator of T cells 
(LAT) that recruits and activates signalling proteins like phospholipase C (PLC) and it 
phosphorylates the exchange factors VAV and SOS, which in turn activate the RAS-RAF-
MAP kinase pathway. Degranulation is the result of sustained calcium mobilization induced 
by IP3 released by PLC activity. Eicosanoids, including leukotrienes and PGD2, are 
generated by conversion arachidonic acid. Arachidonic acid itself is released by the action of 
cytosolic phospholipase A2 (PLA2) that is also activated by the MAPK pathway. Cytokine 
production is dependent on both the calcium signal and the MAPK pathway that activate 
transcription factors including NFAT, AP1 and NF-B. Therefore most, if not all, mediator 
release and production is controlled by the Lyn-Syk activation leading to calcium 
mobilization and the MAPK pathways10, 14-16. 
 
Adapted from Wong et al.17 
 
Syk is essential for mast cell signalling, as a variant of rat basophilic leukemia RBL-2H3 mast 
cells that lacks the expression of Syk, fails to degranulate after FcRI aggregation, although 
the cells still release histamine when stimulated with calcium ionophore18. Furthermore, in 
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bone marrow derived mast cells isolated from Syk -/- mice, there is no FcRI-induced Ca2+ 
mobilization or secretion12.  
As Syk is positioned upstream of the IgE receptor signal transducing pathway, it may 
represent an important target for the treatment of allergic rhinitis.  
Commonly used antihistamines or leukotriene receptor antagonists target only a single 
mediator, whereas the mast cell, upon activation by allergen, is able to produce a large 
number of inflammatory mediators whose activities will be unaffected by such drugs.  
Syk inhibition during an allergic response will block three mast cell functions: the release of 
preformed mediators such as histamine, the production of lipid mediators such as leukotrienes 
and prostaglandins and the secretion of cytokines.  
 
There is a growing body of literature on the importance of Syk in the development of allergic 
inflammation in the lower airways. In animal asthma models, aerosolized Syk antisense 
oligonucleotides (ASO) inhibited many of the central components (f.e. the level of 
eosinophils, tumour necrosis factor) of allergic asthma19, and a Syk-selective tyrosine kinase 
inhibitor prevented mast cell degranulation and airway hyperresponsiveness20, 21. In human 
lung mast cells piceatannol prevented histamine release22. Piceatannol was originally 
described as a syk-specific inhibitor but it inhibits other kinases as well23 and applied at 
concentrations inhibiting IgE-induced mediator release from basophils, it doesn’t act on syk24. 
Syk inhibitor NVP-QAB205 is considered selective for its respective kinase as it doesn’t 
inhibit other signalling steps thought to be downstream of Syk kinase such as ras-ERK 
pathway elements. Furthermore, it inhibits histamine release in human basophils and cultured 
CD 34+ mast cells and it inhibits bronchial smooth muscle contraction in human isolated 
bronchial preparations 25, 26. 
Supplementary with the limited findings of Syk inhibition in the human bronchial biopsies, a 
clinical study, where another specific Syk inhibitor (R112) was applied, demonstrated the 
reduction of symptoms in seasonal allergic rhinitis patients 27.  
 
Syk is not only expressed in mast cells and basophils, but also in eosinophils28, neutrophils29, 
macrophages30, dendritic cells31 and B-cells32. Therefore the contribution of Syk is not only 
limited to Fc receptors. Unlike many other tyrosine kinases Syk has tumorsuppressing 
properties. Increased expression of Syk in neoplastic cells from breast-cancer tumors 
suppresses tumor growth33. Moreover, reduced expression of Syk has been found in patients 
with breast cancer, suggesting possible severe side effects whit longterm using of Syk 
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inhibitors. In a recent phase 2 study, where the efficacy and safety of a Syk inhibitor was 
evaluated in patients with rheumatoid arthritis, some adverse events were reported such as 
diarrhea, hypertension and neutropenia34.  
 
In summary, syk activation is an important upstream event in the pathways activated through 
FcRI and may therefore control the synthesis and release of a whole range of mediators of 
both the early and late allergic responses. In future, specific syk inhibitors might provide a 
new therapeutic possibility in the treatment of upper airway disease with mast cell 
involvement such as allergic rhinitis. 
IKK-2 INHIBITION 
Nuclear factor (NF)-B is major family of transcription factors that regulates multiple cell 
functions. Five mammalian NF-B proteins have been identified including NF-B1 (p50 and 
its precursor p105), NF-B2 (p52 and its precursor p100), RelA/p65, RelB and cRel. The 
predominant form of NF-B in many cell types is a p65:p50 heterodimer35. In unstimulated 
cells, this transcription factor is found in the cytoplasm in an inactive form because of its 
binding to the inhibitory protein, IB (inhibitor of NF-B)36, 37. Upon activation of the cell 
following the stimulation of receptors such as the TNF receptor, Toll-like receptors or the T-
cell receptor (canonical pathway), a signal transduction cascade unravels that leads to the 
activation of the serine-threonine kinase complex (IKK-complex). The IKK complex 
comprises two catalytic subunits, IKK-1 and IKK-2, and a regulatory subunit termed NF-B 
essential modulator (NEMO)35, 38. The IKK-2 subunit seems to have the dominant role in the 
canonical pathway; it phosphorylates IB bound to NF-B. The phosphorylated complex is 
ubiquitinated and degraded to generate the active NF-B. The transcription factor then 
translocates to the nucleus and its active fraction induces the transcription of cytokines, 
chemokines and adhesion molecules such as IL-1, TNF-, IFN-, eotaxin, GM-CSF, ICAM-
1 and VCAM-139, 40.  
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Because both IL1- and TNF- may in turn activate NF-B, the perpetuation of the 
inflammatory process in inflammatory diseases may be explained easily.  
 
IKK-2 inhibitors might prove useful in inflammatory and autoimmune disorders. They are 
expected to be efficacious in rheumatoid arthritis by affecting multiple mechanisms and cell 
types. In the murine collagen induced arthritis model they could inhibit disease severity as 
well as NF-B related cytokines (IL-1, IL-6, TNF- and IFN-)41-43. Furthermore, in 
inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease, characterized by 
chronic relapsing inflammation, IKK-2 inhibitors ameliorated inflammatory responses in mice 
models. They inhibited clinical endpoints such as weight loss and colon thickening. 
Moreover, histological evaluation showed pronounced reduction in the severity of 
inflammation, in addition to diminished disruption of the mucosal epithelium and loss of 
glandular crypts 44. Additionally, IKK-2 inhibition could be beneficial in patients with type 2 
diabetes because the activation of NF-B through IKK-2 induces inflammatory mediators that 
cause insuline resistance45. During insulin resistance tests in mice, IKK-2 inhibition dosed 
intraperitoneally significantly decreased plasma glucose levels46.  
Furthermore NF-B has an essential role in the production of chemokines, cytokines and cell 
adhesion molecules in allergic asthma47. In mice, IKK-2 inhibition suppressed allergen-
induced airway inflammation and hyperreactivity, with inhibition of airway eosinophilia, IL- 
4, IL-5 and IL-1248. Similar results  were reported in an antigen-driven model of airway 
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inflammation in rats and in human airway smooth muscle49, 50; IKK-2 inhibition decreased  
inflammatory cell recruitment, TNF-, IL-1, IL-4, IL-5, IL-13 and eotaxin.  
To our knowledge, there are no reports on IKK-2 inhibition in allergic rhinitis or nasal 
polyposis. However, the NF-B pathway may play an important role in those inflammatory 
diseases. There is a higher gene and protein expression of NF-B in nasal polyps than in 
control mucosa, whereas transcription factor AP-1 does not seem to have a significant role in 
this pathological process51 and the low expression of COX-2 mRNA in nasal polyps from 
aspirin-sensitive patients is associated with a down-regulation of NF-B activity52. In nasal 
cultured epithelium cells from healthy individuals there is an increased expression of the 
transcription factor NF-B and AP-1 related genes in the presence of a house dust mite 
stimulus, and cultured epithelium cells from allergic individuals show already an activated 
NF-B regulatory pathway and upon exposure to house dust mite allergen the AP-1 pathway 
is downregulated53.    
 
There are concerns that inhibition of NF-B may cause side effects such as an increased 
susceptibility to infection, which has been observed in gene disruption studies when 
components of NF-B are inhibited54, 55. Furthermore, it is suggested that IKK-2 may serve 
additional functions beyond regulating the NF-B pathway: the possibility has been raised 
that the IKK family may be involved in control of normal mitosis 56, 57. In addition, IKK-2 
knockout mice do not survive due to liver apoptosis. Teratogenicity and susceptibility to 
infection could be problematic and therefore more information will become available as 
structurally distinct IKK-2 inhibitors progress through pre-clinical safety studies. 
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CHAPTER IV : AIMS OF THE STUDY 
________________________________________________________ 
 
The main objective of this thesis was to develop ex-vivo models to stimulate nasal tissue, 
closely mimicking the natural environment and to use these models to test new 
pharmaceutical molecules. 
 
Chapter V:   to set up an ex-vivo model for early-phase release of mast cell mediators in 
inferior turbinate tissue and nasal polyp tissue. To look for similarities or 
differences in the response of both type of tissues. 
 
Chapter VI:   to set up an ex-vivo model for late-phase release of immunoregulatory and 
proinflammatory cytokines. To stimulate nasal polyps with S. aureus derived 
proteins to further analyse the disease-modifying role of S. aureus in nasal 
polyps. 
 
Chapter VII:  to study the usefulness of a specific syk-kinase inhibitor in inhibiting the 
release of early phase mediators and to compare with the response of in vitro 
cord blood derived mast cells.  
 
Chapter VIII:  to study the usefulness of a specific IKK-2 inhibitor in decreasing SEB-induced 
release of cytokines in nasal polyps and to compare with the effect of 
fluticasone propionate. 
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ABSTRACT 
Background: The mast cell is a crucial effector cell in allergic rhinitis and other inflammatory 
diseases. During the acute allergic reaction preformed mediators such as histamine, but also 
de novo produced mediators such as leukotrienes (LTC4/D4/E4) and prostaglandins (PGD2) are 
released. Mast cells represent targets for therapeutic intervention, and thus a human ex-vivo 
model to stimulate mast cells taken from mucosal sites would be instrumental for drug 
intervention studies. We have aimed to activate mast cells within ex-vivo human nasal tissue 
by IgE/ anti-IgE specific ( chain specific) stimulations and in this respect to test the usability 
of nasal polyps versus inferior turbinates 
Methods: Biopsy samples were collected from patients with nasal polyps and inferior 
turbinates from patients who underwent sinus or septal surgery. Tissue fragments were primed 
with IgE 1µg/ml for 60 minutes and then stimulated for 30 minutes with tissue culture 
medium (negative control), anti-IgE 10µg/ml, anti-IgE 30µg/ml and ionomycin 10µM 
(positive control). Histamine, leukotrienes and PGD2 were measured in supernatants. To help 
provide an understanding of the extent of the response, the number of tryptase and FcRI 
positive cells was evaluated by means of immunohistochemistry and the FcRI-chain was 
measured by means of quantitative PCR in the nasal polyp and inferior turbinate tissues. 
Finally, the correlation between IgE concentrations in the nasal tissue and the release of 
mediators was analysed.  
Results: Stimulations with anti-IgE on IgE-primed nasal tissue fragments lead to a 
concentration-dependent release of histamine, leukotrienes and PGD2. The release of these 
early phase mediators was significantly higher in nasal polyps compared to inferior turbinates, 
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although tryptase, FcRI positive cells and FcRI-chain transcripts were equally present in 
both groups. No correlation was found between baseline concentrations of IgE, and the 
release of histamine, LTC4/LTD4/LTE4 and PGD2 after stimulation. 
Conclusions: This human nasal challenge model mimics the allergic early phase reaction. The 
release of histamine, cys-leukotrienes and PGD2 was significantly higher in nasal polyps 
versus inferior turbinates, however, this observation could not be explained by differences in 
mast cell or FcRI+ cell numbers.  
BACKGROUND 
Mast cells play a crucial role in allergic rhinitis and other inflammatory responses. Positioned 
at mucosal surfaces, these cells are situated to be among the first to encounter antigens that 
elicit allergic reactions. Interaction of multivalent allergens with cell-bound specific 
immunoglobuline E (IgE) leads to cross-linking of the high affinity IgE receptor (FcRI), 
which is primarily expressed on mast cells and basophils. First, this results in the immediate 
release of the content of mast cell secretory granules, which includes preformed mediators 
such as histamine, neutral proteases and proteoglycans and second, it results in the de novo 
synthesis of mediators including the products of the arachidonic acid metabolism, such as 
prostaglandin D2 (PGD2) and sulfidopeptidyl leukotrienes C4/D4/E4, and the production of 
several cytokines (i.e. IL-4, IL-5, IL-6, TNF-, IL-13) 1, 2. During the acute allergic reaction 
mainly preformed mediators such as histamine, but also newly produced mediators such as 
leukotrienes (LTC4/D4/E4) and PGD2 are released 3. These mediators initiate rapid vascular 
permeability, leading to plasma extravasation and tissue edema, mucous overproduction and 
leukocyte recruitment. 
Most early studies of mast cells rely on the use of transformed mast cells from murine 
mastocytoma cells 4, 5. Currently, it is possible to grow human mast cells in vitro. Interleukin 
(IL)-3, IL-6 and stem cell factor (SCF) may act on hematopoietic stem cells present in bone 
marrow, umbilical cord blood, fetal liver or peripheral blood and make it possible to grow 
large numbers of committed mast cell precursors. These cells express high levels of c-kit 
receptor and FcRI 6. Furthermore, several mast cell lines such as HMC-1 7 or LAD-1/2 8 are 
available to study mast cell biology. The use of murine cells, the addition of several factors to 
grow human mast cells, or the use of human mast cell lines may induce responses different 
from primary in vivo tissue mast cells. 
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Considerable difficulties exist to isolate and stimulate mast cells from nasal tissue; especially 
the limited amount of tissue extracted after surgery (turbinotomy) and the low number of mast 
cells isolated from nasal tissue, may give problems to stimulate nasal mast cells directly 9. To 
study nasal mast cells, stimulations have been done in enzymatic dispersed nasal polyp tissue 
10, 11. Accessibility of nasal polyp tissue allows for easy assessment of interaction between 
different cell types in an inflammatory environment; however, enzymatic digestion of tissue 
may possible damage receptors and the comparability of results obtained from nasal polyp 
stimulations to inferior turbinate stimulations is not clear. 
We therefore aimed to study mast cells and basophils in their tissue environment by using 
IgE/ anti-IgE driven ( chain specific) stimulations in human nasal tissue explants without 
enzymatic digestion to closely mimic the in vivo situation. Second we wanted to test the 
usability of nasal polyps versus inferior turbinates in this respect, as polyp tissue is easier to 
obtain in larger quantities. Finally, we aimed to explain differences in the response between 
tissues, and studied tryptase and FcRI+ cell numbers, as well as  baseline concentrations of 
IgE in relation to mast cell responses 12. 
 
METHODS 
Patients 
Nasal tissue was obtained from 8 polyp patients and 8 control patients at the Department of 
Otorhinolaryngology of the University Hospital of Ghent. The ethical committee of the Ghent 
University Hospital approved the study and all patients gave their written informed consent 
prior to inclusion in the study.  
None of the subjects received intranasal corticosteroids, anti-histamines or anti-leukotrienes, 
oral and intranasal decongestants or intranasal anticholinergics within 1 week prior to surgery 
and none of the subjects received oral and/or intramuscular corticosteroids within 4 weeks 
prior to surgery. For female subjects pregnancy or lactation was excluded. 
The control group was composed of samples collected from the inferior turbinates from 
patients undergoing septal surgery and/or turbinotomy because of nasal obstruction, unrelated 
to this study. 
Nasal polyp samples were collected during functional endoscopic sinus surgery. Nasal 
polyposis was diagnosed based on symptoms, clinical examination, nasal endoscopy, and 
sinus computed tomography (CT) scan according to the EP3OS guidelines 13.  
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The atopic status of all patients was evaluated by skin prick tests with a standard panel of 14 
inhalant allergens, including negative (NaCl solution) and positive controls (10 mg/ml 
histamine solution).  The reaction to a skin prick test was considered positive if the wheal area 
caused by the allergen was greater than 7 mm² (diameter >3 mm). Patient characteristics are 
displayed in table 1.  
_______________________________________________________ 
Inferior turbinates           Nasal polyps 
_______________________________________________________ 
N    8       8  
Age (median, range)  36.5   (17-47)                 38.5   (18-54) 
Female/ male   2/6       4/4 
Asthma in history  1/8                                  0/8 
Skin prick test-positive           0/8       2/8 
Aspirin intolerance  0/8       0/8 
Smoking   1/8       1/8 
_______________________________________________________  
Table 1. Patient characteristics 
 
The nasal tissue collected during surgery was immediately transported to the laboratory, 
partly snap frozen in liquid nitrogen, and stored at –80°C until analysis for 
immunohistochemistry, IgE measurement and PCR. The remaining tissue was used for the ex-
vivo stimulations.  
Mechanical disruption and stimulations of human nasal tissue 
The human nasal mucosa and submucosa was cut thoroughly in tissue culture medium 
consisting of RPMI 1640 (Sigma-Aldrich, Bornem, Belgium), containing 2mM L-Glutamine 
(Invitrogen, Merelbeke, Belgium), antibiotics (50 IU/ml penicillin and 50µg/ml streptomycin) 
(Invitrogen) and 0.1% BSA (Bovine Serum Albumin, Sigma). The tissue was passed through 
a mesh to achieve comparable fragments. The tissue fragments (+/- 0.9 mm3) were weighed 
and resuspended as 0.04g tissue/ 1 ml tissue culture medium. The tissue was preincubated for 
1 hour at 37°C, 5% CO2 with 1µg/ml human myeloma IgE (Calbiochem, VWR International, 
Leuven, Belgium). After 3 washing steps the tissue fragments were resuspended in the 
appropriate amount of culture medium and 0.5 ml of this fragment suspension was dispensed 
per well of a 48 well plate. (BD Falcon, VWR, Leuven, Belgium). The fragment suspensions 
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were stimulated with either culture medium (negative control), -chain specific anti-human 
IgE antibody (Dako Belgium N.V., Heverlee, Belgium), at 10 or 30 µg/ml (Dako Belgium 
N.V., Heverlee, Belgium), or 10 µM ionomycin (Calbiochem) for 30 minutes.  
Supernatants were separated by centrifugation and stored immediately at -20°C until analysis 
of histamine, LTC4/D4/E4 and PGD2.  
Measurements of mediators in supernatants of stimulated tissue fragments  
Concentrations of histamine, LTC4/D4/E4 and PGD2 were measured in tissue supernatants 
obtained after the stimulations using ELISA kits for Histamine (IBL Hamburg, Germany), 
LTC4/D4/E4 (Oxford Biomedical Research, Nuclilab BV, Ede, The Netherlands) and PGD2 
(Cayman Chemicals, Ann Arbor, Michigan) following the instructions of the manufacture.  
Immunohistochemistry 
Cryostat sections were prepared (6 µm) and mounted on SuperFrost Plus glass slides (Menzel 
Glaeser, Braunschweig, Germany), packed in aluminium paper and stored at -30°C until 
staining. Sections were immunohistochemically stained with the following antibodies: mouse 
anti human mast cell tryptase (clone G3, Chemicon International, Biognost, Heule, Belgium) 
and mouse anti human FcRI (clone CRA1, Gentaur, Brussels, Belgium). For 
immunohistochemical staining, specimens were fixed in Carnoy’s Fluid (60% ethanol, 30% 
chloroform, 10% glacial acetic acid). Endogenous peroxidase activity was blocked with 0.3% 
hydrogen peroxide in TBS (Tris-buffered-Saline) containing 0.1% sodium azide for 20 
minutes. The primary antibody or the negative control, consisting of the corresponding 
isotype control, was incubated for 1 hour and signal was detected using the LSAB+ technique 
conjugated with peroxidase according to the manufacturer’s instructions (labelled 
streptavidin-biotin; Dako). The peroxidase activity was detected using AEC Substrate 
chromogen (Dako), which results in a red-stained precipitate. Finally the sections were 
counterstained with hematoxylin and mounted. 
The number of positive cells was analysed using a magnification of 400 and scored by two 
independent observers who did not know the diagnosis and clinical data. The analyses 
included 10 relevant fields of the biopsy, and for each sample, the sum of positive cells/10 
fields were scored. 
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RNA preparation and real-time RT-PCR 
Snap frozen tissue samples were placed in liquid nitrogen and thoroughly ground with a 
mortar and pestle and homogenized with Lysis Buffer (Bio-Rad Laboratories, CA, USA). 
Total RNA was purified using the Aurum™ Total RNA Mini Kit (Bio-Rad Laboratories, CA, 
USA) following manufacture’s intructions. One microgram of total RNA was than reverse 
transcribed to generate cDNA with the iScript cDNA Synthesis Kit (Bio-Rad Laboratories, 
CA, USA) as instructed by the supplier. Expression of the IgER-chain was determined using 
real-time PCR performed on an iCycler Real Time Detection System (Bio-Rad Laboratories, 
CA, USA). Primers and probes were purchased from Invitrogen (Merelbeke, Belgium) and 
contained the following sequences: IgER (sense): 5´-TCTTCAGTGACTGGCTGCTCC-3´, 
IgER (antisense): 5´-GCTGGCCCTCCATCACC-3´, IgER-probe: FAM- 5´-
TCAGGCCTCTGCTGAG-3´-TAMRA 14. PCR reaction contained 20ng of cDNA, 300 nM of 
specific primers, 100nM of TaqMan probe and 1X TaqMan Master mix (Bio-Rad 
Laboratories, CA, USA) in a final volume of 0.02ml. Amplification program consisted in 1 
cycle at 95°C for 10 min followed by 40 cycles at 60°C for 1 min and 95°C for 15 seconds. 
The expression of two housekeeping genes: Beta actin (ACTB) and Hydroxymethyl-bilane 
synthase (HMBS) was used to normalize for transcription and amplification variations among 
samples after a validation using the geNorm software as described previously 15. The relative 
expression of the receptor was calculated with the qBase program (version 1.3.5, UGent, 
Belgium) based on the delta-CT relative quantification method. Results are shown as relative 
expression units per 20 ng cDNA (RNA based).  
Measurement of IgE in tissue homogenates  
Snap frozen tissue specimens were weighed, and 1 ml of 0.9% NaCl solution was added per 
every 0.1 g tissue. The tissue was then homogenized with a mechanical homogenizer (B. 
Braun, Melsungen, Germany) at 1000 rpm for 5 min on ice as described previously 16. After 
homogenization, the suspension was centrifuged at 3000 rpm for 10 min at 4°C and the 
supernatants separated and stored at -80°C until analysis. Immunoglobuline E was measured 
by the UNICAP system (Phadia, Uppsala, Sweden). 
Statistical analysis 
Statistical analysis was performed using the Wilcoxon test (for paired comparisons). The 
Mann-Whitney U test was used for between-group (unpaired) comparisons. P values of less 
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than .05 were considered as statistically significant. Correlations were made by using the 
Spearman rank correlation analysis. 
RESULTS 
Mediator release after ex-vivo stimulations 
A stimulation model was set up to stimulate inferior turbinate tissue (n=8) and in larger 
quantities obtainable nasal polyp tissue (n=8). IgE-primed nasal tissue fragments were 
stimulated with anti-IgE (10µg/ml and 30µg/ml) or ionomycin (10µM) for 30 minutes. 
Stimulation resulted in a significant release and production of histamine, leukotrienes and 
PGD2 measured in the supernatants by ELISA. These mediators were released in a 
concentration-dependent manner, except for LTC4/D4/E4 in the inferior turbinate group (Table 
2), where the difference between 10 and 30µg/ml was not statistically significant.  
After 30 minutes culture in medium alone, the spontaneous release of histamine and 
leukotrienes was significantly higher in nasal polyps compared to inferior turbinates (p<0.01 
and  p=0.03 respectively). However, the spontaneous release of PGD2 was not different 
between the two groups (p=0.1). After correction for spontaneous release, the induced release 
of histamine, LTC4/D4/E4 and PGD2 was significantly higher in the nasal polyp group 
compared to the inferior turbinate group, both after stimulation with anti-IgE 10 µg/ml and 
anti-IgE 30 µg/ml (Fig 1). 
 
 
Fig 1. Histamine (ng/ml) (A), LTC4/D4/E4 (ng/ml) (B) and PGD2 (ng/ml) (C) release after 30 minutes anti-IgE 
(10µg/ml and 30µg/ml) stimulation. Comparison between nasal polyps (n=8) and inferior turbinates (n=8) after 
correction for baseline. The box-and-whisker plot represents the median, the lower to upper quartile, and the 
minimum to the maximum value, excluding outside and far out values, which are displayed as separate points. 
Statistical analyses were performed by using the Mann-Whitney U test. * p0.05, ** p0.001.       
          = inferior turbinates,                     = nasal polyps.     
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Immunohistochemistry 
In an attempt to explain the stronger response upon stimulation in nasal polyps versus inferior 
turbinates, mast cells and basophils were stained for tryptase and counted (Fig 2A), but no 
difference in the total numbers of mast cells in the nasal polyp group compared to the inferior 
turbinate group was detected. Furthermore, staining for FcRI showed no differences 
between the numbers of positive cells in both groups (Fig 2B). Representative stainings are 
shown in Fig 3.  
 
 
Fig 2. Numbers of tryptase positive cells (A) and FcRI positive cells (B) in the inferior turbinate group (Inf 
Turb) (n=8) and the nasal polyp group (NP) (n=8), expressed as 10 scored fields (×400). The mRNA expression 
of FcRI in the inferior turbinate group and the nasal polyp group (C). The box-and-whisker plot represents 
the median, the lower to upper quartile, and the minimum to the maximum value, excluding outside and far out 
values, which are displayed as separate points. Statistical analyses were performed by using the Mann-Whitney 
U test. NS= Not Significant 
 
FcRI-chain mRNA 
To study the expression of the high affinity IgE receptor, the amount of FcRI mRNA was 
quantified by RT-PCR in the nasal polyp and inferior turbinate groups. Equivalent FcRI 
mRNA levels were found in nasal polyps compared to inferior turbinates (Fig 2C).  
IgE in tissue homogenates 
As it is described that the concentration of IgE is related12 to the surface expression of FcRI, 
and IgE concentrations are significantly higher in nasal polyps compared to controls 17, we 
studied the correlation between the IgE levels in tissue homogenates, and the release of 
histamine, LTC4/LTD4/LTE4 and PGD2 after anti-IgE challenge. Confirming earlier results, 
the concentrations of IgE were significantly higher in nasal polyps 97.6 (55.3-190.1) kUA/l 
median (IQR) compared to inferior turbinates 10.3 (9.4-30.7) kUA/l (p=0.02). However, 
we were not able to demonstrate any correlation between the concentrations of IgE in nasal 
polyp homogenates and the amount of histamine release (r=0.05, p=0.9) (r=0.1, p=0.8), 
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leukotriene release (r=0.3, p=0.4) (r=0.4, p=0.3) and PGD2 release (r=0.3, p=0.4) (r=0.2, 
p=0.5) after anti-IgE 10µg/ml and anti-IgE 30µg/ml stimulation respectively. Furthermore no 
correlation could be found between the concentrations of IgE in inferior turbinate 
homogenates and the amount of histamine release (r=0.1, p=0.7) (r=0.5, p=0.2), leukotriene 
release (r=0.01, p=1.0) (r=0.5, p=0.2) and PGD2 release (r=0.02, p=1.0) (r=0.8, p=0.1) after 
anti-IgE 10µg/ml and anti-IgE 30µg/ml stimulation respectively. 
 
Fig 3. Representative staining of tryptase positive cells in inferior turbinate tissue (A) and in nasal polyp tissue 
(B). Representative staining of FcRI positive cells in inferior turbinate tissue (C) and in nasal polyp tissue (D) 
( 200). 
 
DISCUSSION 
Until recently, cell systems used for exploration of mast cell biology have mainly been of 
rodent origin (the rat basophilic leukaemia cell line RBL-2H3, mouse bone marrow derived 
mast cells). The only human cell line available (HMC-1) 7 has been of limited usefulness due 
to the cells’ stem cell factor independence, and inconsistent degranulation to IgE-dependent 
signals, presumably due to variable expression of the FcRI-subunit 7, 18. Other cell cultures, 
designated LAD 1 and 2, derived from bone marrow aspirates from a patient with mast cell 
sarcoma/ leukemia, resemble CD34+-derived human mast cells with functional FcRI and 
FcRI receptors 8. The use of bone marrow derived mast cells 19, umbilical cord blood derived 
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mast cells 20, and foetal liver 21 or peripheral blood derived mast cells 19 have improved the 
models for studying mast cell biology 22.  Here, addition of certain interleukins such as IL-3, 
IL-6 or SCF to CD34+ progenitor cells made it possible to grow large numbers of committed 
mast cell precursors. However, mast cells display phenotypic heterogeneity depending on 
their tissue localisation, and any of those surrogate cell systems may prove not to represent 
the mast cells in a diseased tissue. It is therefore advantageous to study mast cells derived 
from human nasal mucosal, especially diseased tissue. 
Pawankar et al 9 were able to isolate mast cells from inferior turbinates and study the IgE 
receptor, however, the number of mast cells remaining after stimulation is too little to perform 
meaningful mast cell activation and mediator release. Several studies 10, 11 have made use of 
mast cells within digested nasal polyp tissue for stimulation, however these cells did not 
release histamine upon IgE receptor stimulation 23.  
 
In this study we stimulated ex-vivo nasal tissue with anti-IgE to study mast cell activation and 
to compare the response in inferior turbinates and nasal polyps. By using whole tissue 
preparations, the cells remained in their natural environment, and unchanged surface receptor 
expression was maintained by omitting enzymatic digestion, thus closely mimicking the in 
vivo situation. 
 The stimulation with anti-IgE 10 µg/ml and anti-IgE 30 µg/ml resulted in a significantly 
higher production and release of mediators such as histamine, LTC4/D4/E4 and PGD2 
compared to baseline, and these mediators were released in a concentration-dependent 
manner. 
Although we measured mediators which are relatively restricted to mast cells such as 
histamine, PGD2 and LTC4/D4/E4, we could not totally exclude that other cells, which have 
been reported to express the IgE receptor, such as dendritic cells 24 and eosinophils 25, may 
also have been activated during this process. However, dendritic cells do not produce and 
release histamine, LTC4/D4/E4 or PGD2, and it is generally accepted that eosinophils are not a 
source of histamine and PGD2. Moreover, it has been shown that stimulation with human IgE 
and anti-IgE does not cause production of leukotriene C4 in eosinophils 26, demonstrating 
only mast cell activation in this setting.  
Theoretically, basophils could contribute to the responses demonstrated here. It is, however 
difficult to discriminate between basophils and mast cells as effector cells. There are no 
reports about the number of basophils in nasal polyps in literature, suggesting a minor role of 
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those cells in nasal polyps. Secondly, in the lamina propria of inferior turbinates of allergic 
patients, at baseline, the number of mast cells is at a median of 88%, with the percentages of 
basophils being as low as 3%. Only after allergen provocation, in the early phase, numbers of 
mast cells diminish sharply to a median percentage of 27% and basophils increase to 23% 27. 
However, in the setting used here, mast cells most probably are the major contributors, as an 
influx of basophils in this ex-vivo model is impossible. Moreover, studies measuring 
mediators in nasal lavage fluid in an allergen-induced late-phase reaction revealed high levels 
of histamine but relatively low levels of products such as PGD2. Since histamine is released  
by mast cells and basophils, but prostaglandin D2 is not produced by basophils, these findings 
have implicated the basophils as an important contributor to histamine release in the late 
phase but not in the early phase28, 29. In the here presented model, we thus most likely restrict 
the stimulation to mast cells.  
 
Accessibility of nasal polyp tissue allows for easy assessment of interaction between different 
cell types in an inflammatory environment; however, the comparability of results obtained 
from nasal polyp stimulations to inferior turbinates was not studied so far. We therefore 
investigated the comparability of release of early mediators in nasal polyps versus inferior 
turbinates. We here demonstrate that the production and release of histamine, LTC4/D4/E4 and 
PGD2 was significantly and consistently higher in nasal polyps compared to inferior 
turbinates, both after stimulation with anti-IgE 10 µg/ml and anti-IgE 30 µg/ml.  
The increased release of early phase mast cell mediators in nasal polyps could be due to the 
presence of a higher number of mast cells in nasal polyps. However, no difference in the total 
number of tryptase-positive cells in inferior turbinates compared to nasal polyps could be 
found by tryptase staining. Literature reports show contradictory findings; it is described that 
the number of epithelial mast cells in nasal polyps is elevated compared to controls30, 31  or 
that there is no difference in number of epithelial mast cells compared to controls17, 32. In line 
with our findings, a recent study couldn’t find any difference in the total number of mast cells 
between nasal polyps and inferior turbinates33.  
It is well described that mast cells in nasal polyps are mostly located in the stroma and are 
more degranulated compared to inferior turbinate mast cells 34, 35. Furthermore, stromal mast 
cells of dispersed nasal polyp tissue release higher amounts of histamine after anti-IgE 
stimulation compared to epithelial mast cells of the same tissue36. This underlines the 
heterogeneity of mast cells in different tissues and could point to a more activated status of 
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polyp versus turbinate mast cells, and a higher sensitivity to external triggers. In line with our 
findings, levels of mast cell-derived mediators such as histamine and tryptase in nasal fluids 
from patients with nasal polyps are significantly higher than those observed in patients 
without nasal polyps 37. Here we show that mast cells, even if partially degranulated in polyp 
tissue, still can produce and release higher amounts of mediators compared to the non-
degranulated mast cells in inferior turbinates.   
Having shown that the number of mast cells present was similar between polyp and turbinate 
tissue, we investigated whether the number of FcRI-positive cells was different between 
the two tissue types, but no difference was shown. The number of FcRI positive cells was 
higher than the number of tryptase positive cells, in both nasal polyps and inferior turbinates, 
which may be explained by the staining of other than mast cells, such as basophils, 
eosinophils 25 and dendritic cells 24. 
Moreover, the FcRI chain expression at mRNA level did not demonstrate any difference in 
relative expression in nasal polyps compared to inferior turbinates. In the past, our group and 
others have described significantly higher levels of IgE in nasal polyp homogenates compared 
to controls 17, 38. As IgE levels may control cell surface levels of FcRI 39, we expected higher 
levels of FcRI mRNA in the nasal polyps, which then could explain the increased release of 
mediators. However, in line with our results, other studies demonstrated that the presence or 
absence of IgE has no influence on the levels of mRNA for either alpha, beta, or gamma 
subunits of FcRI 40, 41. 
In cord blood derived human mast cells, pre-incubation of mast cells for 4 days with IgE 
resulted in an enhancement of the IgE-binding ability of cells, and this was reflected by an 
increased surface expression of FcRI. Moreover, this resulted in the elevated release of 
histamine, LTC4 and PGD2 in response to anti-IgE challenge12. However, we were not able to 
demonstrate a correlation between baseline IgE levels in nasal polyp and inferior turbinate 
homogenates and the amount of histamine, LTC4/LTD4/LTE4 or PGD2 release upon 
stimulation. Moreover, the release of mediators also was significantly different in polyp 
versus turbinate tissue after ionomycin stimulation, suggesting that the higher release in nasal 
polyps might be unrelated to the surface expression of FcRI. Further studies need to clarify 
the mechanism behind this phenomenon. 
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_________________________________________________________________________________________________ 
                                    Histamine (ng/ml)                    LTC4/LTD4/LTE4 (ng/ml)               PGD2 (pg/ml) 
____________________________________________________________________________________________________ 
Nasal polyps 
RPMI 24.1 (15.1-32.6) 0.0815 (0.048-0.11) 109 (66.5-221) 
Versus p<0.01 p<0.01 p<0.01 
Anti-igE 10µg/ml 43.2 (28.1-55.5) 0.469 (0.348-0.816) 1960 (1518-4544) 
Versus p<0.01 p<0.01 p<0.01 
Anti-IgE 30µg/ml 63.6 (44.8-75.5) 0.675 (0.561-1.21) 4949 (2991-6152) 
Ionomycin 10µM 130 (77.5-135) 3.40 (1.80-5.37) 2717 (1364-4298) 
Versus baseline p<0.01 p<0.01 p<0.01 
 
Inferior turbinates  
RPMI 8.5 (5.6-12.9) 0.036 (0.016-0.0395) 58.6 (40.2-88.2) 
Versus p<0.01  p<0.01 p<0.01 
Anti-igE 10µg/ml 16.2 (12.0-20.2) 0.0655 (0.038-0.181) 840 (492-1269) 
Versus p<0.05 p=0.44 p<0.05 
Anti-IgE 30µg/ml (n=6)  28.1 (21.8-31.7) 0.0715 (0.058-0.331) 1669 (1311-1732) 
Ionomycin 10µM 27.6 (22.3-45.5)  0.361(0.24-0.525) 967 (548-1373) 
Versus baseline p<0.01  p<0.01 p<0.01 
____________________________________________________________________________________________________ 
 
Table 2. Overview of anti-IgE and ionomycin-induced release of histamine (ng/ml), LTC4/LTD4/LTE4 (ng/ml) and 
PGD2 (pg/ml) after 30 minutes in the nasal polyp (n=8) and inferior turbinate group (n=8). Data are expressed 
as median +/- IQR. 
Statistical analysis; Wilcoxon-test 
 
CONCLUSIONS                                                                                                                                    
To conclude, a whole tissue nasal mucosal stimulation model was established which can be 
used to mimic the early phase of an allergic reaction both in nasal polyps and inferior 
turbinates.  
We observed a significantly higher release of mast cell mediators after equivalent stimulation 
of nasal polyp tissues compared to inferior turbinates, the mechanism of which remains 
unclear. It is well recognized that mast cells with distinct functional and histochemical 
properties are present in human tissues 42, 43. The functional heterogeneity, the micro-
environmental forces that dictate responsiveness and the impact of disease on mast cell 
response might be important in this process. 
As high amounts of nasal polyp tissue are easier to access, and as nasal polyps and inferior 
turbinate tissue react in the same concentration- dependent manner to IgE- dependent triggers, 
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nasal polyp tissue could be used to study the effect of inhibitors of the allergic early phase 
reaction in future settings. 
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ABSTRACT 
Background: Increasing evidence points towards a modifying role of Staphylococcus aureus 
and its products in the pathogenesis of nasal polyposis.  
Objective: The aim of this study was to investigate cytokine and mediator production after 
stimulation with Staphylococcus aureus derived proteins enterotoxin B, protein A and 
lipoteichoic acid in nasal polyp and control inferior turbinate tissue.  
Methods: Tissue fragments were stimulated with RPMI (negative control), enterotoxin B, 
protein A and lipoteichoic acid for 30 minutes and 24 hours. Supernatants were measured by 
Multiplex for pro-inflammatory cytokines (IL-1, tumor necrosis factor-) and T cell and 
subset related cytokines (interferon-, IL-2, IL-4, IL-5, IL-8, IL-10, IL-12p70, IL-13). 
Histamine, transforming growth factor-1, cysteinyl leukotrienes and prostaglandin D2 were 
analysed by ELISA. 
Results: 30 minutes protein A stimulation resulted in a significant increase of histamine, 
leukotrienes and prostaglandin D2. Enterotoxin B stimulation over 24 hours induced a 
significant increase of IL-1, tumor necrosis factor-, interferon-, IL-2, IL-4, IL-5, IL-10 
and IL-13 in both groups, this increase being significantly higher in nasal polyps compared to 
controls.  
Conclusions: We here show that Staphylococcus aureus products have various effects on 
mucosal tissues: surface protein A induces mast cell degranulation, whereas enterotoxins 
induce the release of cytokines, with a Th2-skewed pattern in nasal polyps, supporting the 
stimulatory role of superantigens in the development of this inflammatory disease. 
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Clinical Implications: Staphylococcus aureus products affect inflammation in nasal polyps by 
inducing mast cell degranulation and T-cell activation.   
CAPSULE SUMMARY 
This study for the first time demonstrates that Staphylococcus aureus derived enterotoxin B 
can polarize mucosal inflammation in polyp tissue to a Th2-pattern, and protein A induces 
mast cell degranulation. 
INTRODUCTION 
Chronic rhinosinusitis with nasal polyposis (NP) is a chronic inflammatory disease of the 
paranasal sinuses, associated with Th2-biased inflammation1, an increase of tissue 
eosinophils2 and polyclonal IgE production, not related with the allergic status of the 
patients3. The mast cells in the stroma of nasal polyps are often degranulated4, 5. In the general 
population the prevalence of NP ranges from 1 to 4% and the precise mechanism underlying 
the pathogenesis of NP is unknown and probably multifactorial2, 6.  
The colonization rate with Staphylococcus aureus (S. aureus) in the middle meatus is 
increased in patients with NP versus controls7. These bacteria express a number of surface 
proteins such as lipoteichoic acid (LTA) and protein A (SpA) that have the potential to 
interfere with host defence mechanisms. LTA has been suggested to be essential for nasal 
colonization and interaction with human nasal epithelial cells8 and SpA has been 
demonstrated to increase histamine release from human basophils9 and human heart mast 
cells10. SpA appears to activate basophils by interacting through its alternative binding site 
with immunoglobuline E (IgE) VH3+ bound to the high affinity IgE receptor (FcRI) 9, 10. In 
addition, SpA has been proposed to have B-cell superantigenic effects11, 12.  
Moreover, S. aureus secretes several toxins with superantigen activity namely the S. aureus -
derived enterotoxins (SAEs) and the toxic shock syndrome toxin (TSST-1). Superantigens for 
T-lymphocytes have the ability to crosslink the class II major histocomptability complex of 
antigen-presenting cells and the T-cell receptor (TCR) β-chain variable regions. This 
crosslinking takes place outside the conventional antigen-binding grove, and may lead to the 
stimulation of up to 20-25% of the T-cell population in a non-specific way, compared with 
stimulation of only about 0.1% via the conventional allergen-specific way13. Once activated, 
T-cells may produce interleukins (IL) including IL-4, IL-5, IL-13, eotaxin and many others, 
which may lead to an eosinophilic inflammation and local IgE-production.  
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Specific IgE (sIgE) against SAEs is found more frequently in NP versus controls and 
correlates with higher levels of IL-5, eotaxin and eosinophil cationic protein (ECP)2. 
Moreover, an increased number of T cells expressing the TCR -chain variable region, known 
to be induced by microbial superantigens, was detected in NP and correlated with the 
presence of sIgE against SAEs14. A recent study of our group demonstrated that NP was 
predominantly characterized by increased Th2- cytokines such as IL-5, eotaxin, IL-2sRalpha 
and IgE compared to controls1.  
The present study sought to elucidate the modulatory effects of the S. aureus surface proteins 
SpA, LTA and the S. aureus enterotoxin B (SEB) in nasal polyp tissue and to determine 
possible differences from normal nasal (control) tissue. The following cytokines were 
measured: pro-inflammatory cytokines (IL-1, tumor necrosis factor (TNF)-), T cell and 
subset related cytokines (interferon (IFN)-, IL-2, IL-4, IL-5, IL-8, IL-12p70, IL-13,) and 
immunoregulatory cytokines (IL-10, transforming growth factor (TGF)-1). Furthermore, 
mediators such as histamine, cysteinyl leukotrienes and prostaglandin D2 were analysed to 
determine the response of local mast cells. 
METHODS 
Patients 
Nasal tissue was obtained from 25 patients at the Department of Otorhinolaryngology of the 
University Hospital of Ghent. The ethical committee of the Ghent University Hospital 
approved the study and all patients gave their written informed consent prior to inclusion in 
the study. None of the subjects received intranasal corticosteroids, anti-histamines or anti-
leukotrienes, oral and intranasal decongestants or intranasal anticholinergics within 1 week 
prior to surgery and none of the subjects received oral and/or intramuscular corticosteroids 
within 4 weeks prior to surgery. For female subjects pregnancy or lactation was excluded. 
Nasal polyp samples were collected during functional endoscopic sinus surgery from 12 
patients (median age 43 years, ranging from 24 to 67 years old, 10 male and 2 female 
patients). Nasal polyposis was diagnosed based on symptoms, clinical examination, nasal 
endoscopy, and sinus computed tomography (CT) scan according to the EP3OS guidelines15. 
Furthermore samples were collected from inferior turbinates (controls) from 13 patients 
undergoing septal surgery and/or turbinotomy because of nasal obstruction (median age 29 
years, ranging from 22 to 62 years old, 8 male and 5 female patients).  
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The atopic status of all patients was evaluated by skin prick tests with a standard panel of 14 
inhalant allergens. The reaction to a skin prick test was considered positive if the wheal area 
caused by the allergen was greater than 7 mm² (diameter >3 mm). Negative and positive 
controls (10 mg/ml histamine solution) were included with each skin prick test. Five inferior 
turbinates and five NP were obtained from patients with positive skin prick test for at least 
one of the most common aeroallergens. 
Two NP patients reported mild asthma in history, and all patients were free of aspirin 
intolerance. Three control patients and one NP patient reported to smoke cigarettes. 
The nasal tissue collected during surgery was immediately transported to the laboratory and 
divided into two parts. One part was immediately snap frozen in liquid nitrogen and stored at 
–80°C until analysis for immunohistochemistry and until homogenisation. The remaining 
tissue was used for the ex-vivo stimulations.  
Mechanical disruption and stimulations of human nasal tissue 
The human nasal mucosa and submucosa was cut thoroughly in tissue culture medium 
consisting of RPMI 1640 (Sigma-Aldrich, Bornem, Belgium), containing 2mM L-Glutamine 
(Invitrogen, Merelbeke, Belgium), antibiotics (50 IU/ml penicillin and 50µg/ml streptomycin) 
(Invitrogen) and 0.1% BSA (Bovine Serum Albumin, Sigma). The tissue was passed through 
a mesh to achieve comparable fragments. The tissue fragments (+/- 0.9 mm3) were weighed 
and resuspended as 0.04g tissue/ 1 ml tissue culture medium. 
As SpA interacts with immunoglobuline E VH3+ 10, the tissue was preincubated for 1 hour at 
37°C 5% CO2 with 1µg/ml human myeloma immunoglobuline E (Calbiochem, VWR 
International, Leuven, Belgium). After 3 washing steps the tissue fragments were resuspended 
in the appropriate amount of culture medium and then the fragments were divided into a 48 
well plate (BD Falcon, VWR, Leuven) filled with 0.5 ml tissue fragment suspension in each 
well.  
In a following step the tissue fragments (inferior turbinates n=13, NP n=12) were stimulated 
with culture medium (negative control) and 0.5 µg/ml SEB (Sigma-Aldrich) for 30 minutes 
and 24 hours. A  subgroup of patients (inferior turbinates n=8, NP n=8) also was stimulated 
with 10µg/ml SpA (Sigma-Aldrich) and 10µg/ml LTA (Sigma-Aldrich), both for 30 minutes 
and 24 hours. 
After that, tissue fragments and supernatants were separated by centrifugation. Aliquots of the 
supernatants were taken and stored immediately at -20°C until analysis of cytokines and 
histamine, LTC4/D4/E4 and PGD2. 
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Measurements of mediators in supernatants of stimulated tissue fragments  
Concentrations of IL-1, TNF-, IFN-, IL-2, IL-4, IL-5, IL-8, IL-10, IL-12p70 and IL-13 
(2.4-10000 pg/ml) were measured on tissue supernatants obtained after the ex-vivo 
stimulations using Multi-spot assays (Meso Scale Discovery, Maryland) following the 
instructions of the manufacture. The plates were analysed using a Sector Imager 6000 (Meso 
Scale Discovery). 
Concentrations of histamine (2.7-219 ng/ml), LTC4/D4/E4 (0.0313-2 ng/ml), PGD2 (2-250 
pg/ml) and TGF-1 (7.8-1000 pg/ml) were measured using ELISA kits: Histamine (IBL 
Hamburg, Germany), LTC4/D4/E4 (Oxford Biomedical Research, Nuclilab BV, Ede, The 
Netherlands), PGD2 (Cayman Chemicals, Ann Arbor, Michigan) and TGF-1 (R&D Systems 
Europe Ltd, Abingdon, United Kingdom) following the instructions of the manufacturer. 
Measurement of IgE to SAEs mix in tissue homogenates 
Snap frozen tissue specimens were weighed, and 1 ml of 0.9% NaCl solution was added per 
every 0.1g tissue. The tissue was then homogenized with a mechanical homogenizer (B. 
Braun Melsungen, Germany) at 1,000 rpm for 5 minutes on ice as described previously. After 
homogenization, the suspension was centrifuged at 3,000 rpm for 10 minutes at 4°C and the 
supernatants were separated and stored at -80°C until analysis. All samples were assayed for 
IgE to SAEs (staphylococcus enterotoxin A, C and TSST-1) (0.35-100 kUA/l) by the 
UNICAP system (Pharmacia, Uppsala; Sweden). 
Immunhistochemistry 
Cryostat sections were prepared (6µm) and mounted on SuperFrost Plus glass slides (Menzel 
Glaeser, Braunschweig, Germany), packed in aluminium paper and stored at -30°C until 
staining. Sections were immunohistochemically stained with the following mouse monoclonal 
antibody:  CD3 (clone UCHT1, Dako, Glostrup; Denmark) to compare the number of T cells 
in inferior turbinates and NP.  
For immunohistochemical stainings specimens were fixed in acetone. Endogenous peroxidase 
activity was blocked with 0.3% hydrogen peroxide in TBS containing 0.1 % sodium azide for 
20 minutes. Primary antibody or negative control, consisting of the corresponding isotype 
control, were incubated for 1 hour and detected using the LSAB+ technique conjugated with 
peroxidase according to the manufacture’s instructions. (Labelled streptavidin-biotin, Dako). 
The peroxidase activity was detected using AEC Substrate chromogen (Dako), which results 
in a red stained precipitate. Finally sections were counterstained with hematoxylin and 
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mounted.  
The number of positive cells was analysed using a magnification of 400x and scored by two 
independent observers who did not know the diagnosis and clinical data. A grading scale from 
0 to 3 was applied, ranging from absent to numerous stained cells. Score 0 represents no 
positive cells, score 1 <10 positive cells/field, score 2:10-100 positive cells/field and score 3: 
>100 positive cells/field. The analysis included all areas of the biopsy and for each sample 10 
fields were scored.  
Statistical analysis 
Statistical analysis was performed using the Wilcoxon test (for paired comparisons). The 
Mann-Withney U test was used for between-group (unpaired) comparisons. P values of less 
than .05 were considered as statistically significant. Results are expressed as median +/- IQR 
(interquartile range). 
RESULTS 
 
Fig 1. Effect of 24 hours SEB (0.5 µg/ml) stimulation compared to RPMI on IFN-, IL-13, IL-5, IL-4, IL-2, TNF-
, IL-1, IL-10, IL-8, IL-12p70 and TGF-1 release. Comparison between nasal polyps (NP) (n=12) and 
inferior turbinates (IT) (n=13). * p<0.05, ** p<0.01.   
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SEB stimulations 
The inferior turbinates (n=13) and the nasal polyp explants (n=12) were stimulated for 30 
minutes and for 24 hours with culture medium alone (RPMI) and SEB (0.5 µg/ml). SEB 
stimulation for 30 minutes did not increase the release of cytokines in comparison with 
culture medium alone in controls or NP (results not shown).  
24 hours SEB stimulation demonstrated a significant increase of Th1 and Th2 cytokines (IFN-
, IL-2, IL-4, IL-5, IL-10 and IL-13) in inferior turbinates and NP compared to RPMI, but not 
for IL-8, IL-12p70 and TGF-1. The release of these cytokines in NP was significantly higher 
compared to inferior turbinates for all measured cytokines, except for IL-8, IL-12p70 and 
TGF-1. The pro-inflammatory cytokine IL-1 only demonstrated a significant increase in 
NP and TNF- showed a release pattern similar to the above mentioned cytokines (Figure 1).   
After 24 hours in RPMI, a significantly higher release was noticed for IL-13, IL-5, TNF- 
and IL-10 in NP tissue (Table 1). No difference in release could be found between the allergic 
patients and the non-allergic patients. 
 
Table 1. Concentrations of cytokines in supernatants after 24 hours in RPMI (spontaneous release).  
___________________________________________________________________________________________________ 
Inferior Turbinates                   Nasal Polyps                                   p-value 
____________________________________________________________________________________________________ 
 
IFN- (pg/ml) 57.0 (44.3-68.2)  84.3 (61.5-136.0)   =0.1 
IL-13 (pg/ml)          16.5 (8.6-18.2)  42.4 (35.1-54.9)   <0.0001 
IL-5 (pg/ml)          13.0 (12.0-14.1)  17.0 (16.1-18.7)   =0.0003  
IL-4 (pg/ml)          5.5 (4.8-5.9)   5.1 (2.9-5.9)   =0.36 
IL-2 (pg/ml)          186.2 (101.6-235.2)  202.5 (164.2-265.8)  =0.34 
TNF- (pg/ml)          54.2 (38.9-98.9)  129.0 (95.6-191.5)  =0.007 
IL-1 (pg/ml)          355.7 (67.4-989.2)  692.0 (253.5-981.5)  =0.29 
IL-10 (pg/ml)          104.7 (93.5-134.8)  390.9 (288.6-584.7)  =0.0001 
IL-8 (pg/ml)          8860.2 (2458.5-12122.2) 6563.8 (4082.1-9105.4)  =0.27 
IL-12p70 (pg/ml)         7.3 (6.2-7.9)  7.4 (6.2-9.7)   =0.41 
TGF-1 (pg/ml)          275.5 (172.6-377.9)  236.7 (224.0-363.2)  =0.67 
____________________________________________________________________________________________________ 
Inferior turbinates (n=13) versus nasal polyps (n=12). Data are expressed as median +/- IQR (interquartile 
range). 
 
 
 The cryostat sections were stained for CD3 and semi-quantitatively scored. No difference in 
the number of T lymphocytes could be found between inferior turbinates and NP (results not 
shown). 
A ratio was calculated between the concentrations of cytokines in culture medium and after 
SEB stimulation, both for NP and inferior turbinates, and compared to each other (Table 2). 
81
Chapter VI – SEB, Protein A and lipoteichoic acid stimulations in nasal polyps 
Strikingly, the relative increase in cytokine release in NP was highest (above 2) for IL-5, IL-4 
and IL-2, but lowest (0.58) for IL-10 and TGF-1 (0.73). 
SEB did not show an effect on mast cells derived cytokines; after 30 minutes (Fig. 2A) and 24 
hours stimulation (Fig. 2B), no increase could be found for histamine, LTC4/D4/E4 and PGD2 
in either group. None of the samples were positive for IgE to SAEs (results not shown).  
 
Table 2. Ratio of cytokine concentrations after SEB (0.5 µg/ml) stimulation and RPMI for 24 hours.  
__________________________________________________________________________________________________ 
Inferior Turbinates                   Nasal Polyps       Ratio  (NP/IT)                            
__________________________________________________________________________________________________ 
 
IFN- 54.1   70   1.29 
IL-13            3.6    4.5   1.25   
IL-5            1.2    4.3   3.58   
IL-4            2    5.8   2.9   
IL-2            5.6    12.3   2.2   
TNF-            1.8    2.7   1.5   
IL-1            1.5    2.3   1.53 
IL-10            2.6    1.5   0.58 
IL-8            1.3    1.2   0.92  
IL-12p70           1.2    2   1.67 
TGF-1           1.1    0.8   0.73 
__________________________________________________________________________________________ 
Inferior Turbinates (IT) (n=13) versus nasal polyps (NP) (n=12). 
 
SpA and LTA stimulations 
30 minutes SpA stimulation induced a significant increase of histamine, LTC4/D4/E4 and 
PGD2 compared to culture medium in inferior turbinates and NP (Fig. 2A). Howewer, no 
increase of Th1/Th2 cytokines or pro-inflammatory cytokines was measured after SpA and 
LTA short-time stimulation in comparison with culture medium alone. After 24 hours 
stimulation with SpA, the production of cysLTs remained significantly increased in inferior 
turbinates and NP compared to culture medium (Fig. 2B). Furthermore IL-5 was significantly 
increased in NP, and IL-13 demonstrated an increasing trend, not reaching significance 
though (Fig 3).  
Stimulation with LTA for 30 minutes and 24 hours did not induce any increase in Th1/Th2 or 
pro-inflammatory cytokines (results not shown), nor in histamine, LTC4/D4/E4 and PGD2 (Fig. 
2A and 2B).  
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Fig 2. (A) Effect of 30 minutes stimulation with RPMI (baseline), SEB (0.5 µg/ml), SpA (10 µg/ml) and LTA (10 
µg/ml) on histamine, LTC4/D4/E4 and PGD2 release in nasal polyps (NP) (n=8) and inferior turbinates (IT) 
(n=8). (B) Effect of 24 hours stimulation with RPMI (baseline), SEB (0.5 µg/ml), SpA (10 µg/ml) and LTA (10 
µg/ml) on histamine, LTC4/D4/E4 and PGD2  release in nasal polyps (NP) (n=8) and inferior turbinates (IT) 
(n=8).  * p<0.05, ** p<0.01.  
 
DISCUSSION   
We here shown that staphylococcal products have different effects on nasal mucosal samples: 
SpA after 30 minutes resulted in the early release of mast cell mediators including histamine, 
LTC4/D4/E4 and PGD2, whereas SEB after 24 hours induced a late-phase release of numerous 
immunoregulatory and pro-inflammatory cytokines, favouring Th2-cytokines and 
disfavouring IL-10 and TGF-1 in nasal polyps.  
There is increasing evidence that the colonization of S. aureus and the release of its cell 
products may be linked to the inflammation in NP3, 7. In NP, increased rates of S. aureus 
colonization were found7 and sIgE against SAEs was more frequently present in NP versus 
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controls and correlated with higher levels of IL-5, eotaxin and eosinophil cationic protein 
(ECP)2. With the role of S. aureus as disease modifier being suggested, a number of 
diagnostic and therapeutic approaches such as antibiotic treatment or S. aureus vaccination 
may be considered. The potential effect of S. aureus eradication in sinus disease has not been 
studied yet, but large-scale double blind placebo controlled studies are currently ongoing. 
However, in atopic dermatitis, the role of S. aureus and the use of antibiotic treatment has 
already been established. Antimicrobial treatment leads to a significant, albeit temporary 
improvement of atopic dermatitis in patients who are colonized with S. aureus16. 
 
 
 
Fig 3. Effect of 24 hours stimulation with SpA (10 
µg/ml) compared to RPMI on IL-13 and IL-5 in 
inferior turbinates (IT) (n=8) and nasal polyps (NP) 
(n=8). ** p<0.01, NS= not significant.  
 
 
 
S. aureus secretes several enterotoxins with superantigen activity. Superantigens induce large-
scale stimulation of T lymphocytes by a mechanism distinct from conventional antigen 
presentation, involving direct class II major histocomptability complex binding and 
stimulation of TCR families based on Vbeta gene usage17, 18. In this study, 24 hours 
stimulation with SEB induced a remarkable mean increase of IFN- (54 times and 70 times 
more for inferior turbinates and NP, respectively, compared to culture medium) and a 
substantial mean increase of IL-2 (5.6 times for inferior turbinates and 12.3 times for NP). 
However, this release is not reflected in tissue concentrations of patients with chronic nasal 
polyposis. A recent study of our group revealed significantly higher IL-5 protein 
concentrations (used as a Th2-marker) in NP homogenates versus controls, whereas IFN- (a 
Th1-marker) did not demonstrate any difference1. In line with these results, we have 
demonstrated, in the supernatants of tissue fragments cultured for 24 hours with medium 
alone, a significantly higher expression of IL-5 in NP compared to inferior turbinates  
(p=0.0003), but no difference in IFN- expression (p=0.1). Furthermore, when stimulated 
with SEB, the cytokine production was further skewed to IL-5, IL-4 and IL-2, but not to IFN-
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, in NP. Concomitantly, the production of IL-10 and TGF-1 decreased, indicating a possible 
lack in T-cell regulation induced by SEB.  
In other inflammatory diseases similar effects of SEB were described. Peripheral blood 
mononuclear cells from patients with active atopic eczema/dermatitis syndrome or asthma 
and non-atopic controls secreted increased levels of IL-5, IL-4, IL-13 and IFN- in response 
to SEB. Only IL-5 and IL-13 were significantly higher in active atopic eczema/dermatitis 
syndrome or asthma compared to non-atopic controls19, 20.  
 S. aureus enterotoxin B not only has effects on T lymphocytes, but may also affect directly 
the eosinophil activity by upregulating cell-surface expression of antigens and by inhibiting 
the eosinophil apoptosis21. Furthermore, SEB induced IL-12p40 production in peritoneal mice 
macrophages22 and a culture of corneal epithelial cells has been shown to release IL-8 
following treatment with SEB23. In this study, however, neither IL-12p70 nor IL-8 were 
upregulated after SEB stimulation in inferior turbinates and NP. However, similar ex vivo 
studies are required because results of animal studies can’t necessarily be projected on 
humans. 
By measuring mediators such as histamine, LTC4/D4/E4 and PGD2 the responses of specific 
cells, such as mast cells, were analyzed. No increase was measured for these mediators in 
inferior turbinates and NP after 30 minutes and 24 hours stimulation, which may demonstrate 
the lack of direct effect of SEB in releasing mast cell mediators. In line with our results, SEB 
was not shown to release histamine from a human mast-cell line (HMC-1) and led to a dose-
dependent inhibition of IL-4 release24. Other studies however demonstrated opposite results. 
Peripheral blood basophils from patients with atopic eczema stimulated with SEB, secreted 
significantly higher amounts of histamine and leukotriene C4 than peripheral blood basophils 
from healthy controls25 and in rodent mast cells cultures, serotonin was released after SEB 
stimulation26. As none of the patients were positive for sIgE against SAEs, we could not 
demonstrate here the conventional allergen-mediated reaction in mast cells, basophils and 
Fcepsilon-receptor bearing cells after SEB stimulation. In a previous report it was 
demonstrated that isolated basophils released histamine in response to SEB only when 
patients had sIgE against SEB27. The role of IgE and its functionality needs to be further 
studied. 
In contrast, stimulations with SpA, which is a surface protein on S. aureus, demonstrated an 
increase of histamine, LTC4/D4/E4 and PGD2. Marone and colleagues described an increased 
histamine release after SpA stimulation in basophils9 and in human heart mast cells10. SpA 
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has a classical site that binds to Fc, a constant region of IgG28, and an alternative site that 
binds the Fab portion of human polyclonal IgM, IgA, IgG and IgE29. Protein A’s releasing 
activity is mediated by interaction with the commonly expressed VH3 region of IgE, bound to 
the FcRI10. The concept of the classical superantigens (SAEs and TSST-1) applied to the 
pathophysiology of allergic disorders, led to the definition of “superallergens” to indicate 
proteins of various origins able to activate FcRI+ cells by interacting with membrane-bound 
IgE29. Our results support the “allergenic” effect of SpA, as, in contrast to SEB, inferior 
turbinate and nasal polyp tissue, stimulated with SpA did give a significant increase of 
histamine, LTC4/D4/E4 and PGD2, already after 30 minutes. As colonization of S. aureus is 
present in 63.6% of subjects with NP, with rates as high as 66.7% and 87.5% in the subgroups 
with asthma and aspirin sensitivity compared to rates of 33.3% in controls7, not only SEB, but 
also SpA may be relevant in the contribution of the ongoing inflammation in NP.  
No increase of Th1/Th2 cytokines or pro-inflammatory cytokines was measured after SpA 
stimulation in comparison with culture medium alone, except for IL-5 in NP after 24 hours, 
again emphasising the limited influence of SpA on T cells. 
Finally, stimulations with LTA were performed, as LTA is known to be important in the 
interaction of S. aureus with human nasal epithelium cells8. LTA stimulation on nasal tissue 
did not induce any increase of Th1/Th2 cytokines, pro-inflammatory cytokines or mast cell 
derived mediators, clearly reflecting the limited role of LTA in the inflammatory scene in NP. 
In future, similar experiments may be done to approach the role of other agents such as 
viruses, fungi and atypical bacteria in inducing inflammation in nasal mucosal tissue. 
 
In conclusion, these results support the hypothesis that S. aureus may be linked to the 
inflammation in NP. Its enterotoxin SEB is able to induce the release of Th1/Th2-derived and 
pro-inflammatory cytokines in nasal tissue, with significantly higher release in NP compared 
to controls. The production is in favour of Th2 cytokines such as IL-5, IL-4 and IL-2 and 
disfavoured IL-10 and TGF-1. SEB does not appear to have any allergenic effect in nasal 
tissue. In contrast, SpA, a surface protein of S. aureus, has clearly different properties and is 
able to increase histamine, LTC4/D4/E4 and PGD2 release in nasal tissue, which demonstrates 
its allergenic effect and moreover, may therefore, be an additional factor in causing or 
exacerbating the inflammation in NP.  
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ABSTRACT 
Background: Mast cells are crucial effector cells in the allergic cascade. The cross-linking of 
the high affinity IgE receptor (FcRI) activates mast cells and basophils. Spleen tyrosine 
kinase (Syk) is positioned upstream of the IgE receptor signal transducing pathway and may 
represent an important target for the treatment of nasal inflammatory diseases.  
Objective: We therefore aimed to look at the effect of a specific Syk inhibitor in the release of 
mast cell mediators in human cord blood-derived mast cells (in-vitro) and in human nasal 
tissue (ex-vivo). 
Methods: Surgical samples were collected from patients with nasal polyposis who underwent 
sinus surgery. Tissue cubes of +/- 0.9 mm3  were primed with myeloma IgE (1µg/ml), 
preincubated with Syk inhibitor NVP-QAB205 in different concentrations and then stimulated 
with tissue culture medium, anti-IgE 10µg/ml and anti-IgE 30µg/ml. Supernatants were 
analysed for concentrations of histamine, LTC4/LTD4/LTE4  and PGD2. Cord blood-derived 
mast cells were likewise pre-incubated with compound, prior to stimulation with anti-IgE at 
10µg/ml. 
Results: In cord blood-derived mast cells (CBDMCs) the Syk inhibitor prevented the 
degranulation assessed by measurement of histamine release and the production of 
LTC4/LTD4/LTE4 and PGD2. Furthermore, the Syk inhibitor was similarly able to 
significantly inhibit the release of these granule and newly synthesized mediators by nasal 
polyp mast cells in a dose dependent manner.  
Conclusion: Although the critical role of Syk in the IgE receptor signal transduction pathway 
has been well documented in vitro, this study supports the importance of Syk in IgE receptor-
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mediated degranulation of mast cells ex-vivo within nasal tissue. Thus, inhibition of Syk may 
represent an important therapeutic strategy for the treatment of upper  
airway disease with mast cell involvement, such as allergic rhinitis. 
INTRODUCTION 
Mast cells are multifunctional effector cells of the immune system and play a crucial role in 
the allergic response. Activation of these cells induces the release of a wide collection of 
mediators which initiate the cascade of clinical symptoms associated with allergic rhinitis 
such as itching, sneezing, rhinorrhea and nasal obstruction1. First of all there is the release of 
preformed inflammatory mediators such as histamine and tryptase localized in specialized 
granules and secondly there is  the de novo synthesis and secretion of cytokines, chemokines, 
and eicosanoids 1, 2. During the acute allergic reaction there is mainly the release of preformed 
mediators such as histamine but also the release of newly formed leukotrienes (LTC4/D4/E4) 
and prostaglandin D2 (PGD2)3. 
The IgE/ allergen –mediated stimulation through the cross-linking of the high-affinity 
receptor for IgE (FcRI) remains a very important step in the activation of the mast cell. The 
FcRI expressed on mast cells and basophils is a tetrameric receptor comprised of the IgE-
binding  chain, the signal-amplifying  chain4 and the two signal transducing  chains5. The 
transmission of the signals is dependent on the specific sequence of the immunoreceptor 
tyrosine-based activation motif (ITAM) present on the  and  chains. After the 
phosphorylation of the ITAMs by the protein tyrosine kinase Lyn, there is the activation of 
spleen tyrosine kinase Syk through ITAM binding 6, 7. Furthermore there is the activation of 
several adaptor proteins and transcriptional factors. The activation of FcRI finally leads to 
degranulation, cytokine and eicosanoid production of mast cells. 
Consequently, as Syk is positioned upstream in the cell signalling pathway, therapies 
targeting Syk should block three mast cell functions: The release of preformed mediators such 
as histamine, the production of lipid mediators such as leukotrienes and prostaglandins and 
the secretion of cytokines8.  
We have demonstrated before9 that nasal polyp tissue can be used for testing the early phase 
of an allergic reaction. As large amounts of nasal polyp tissue are easier to access than inferior 
turbinate tissue, and as nasal polyps and inferior turbinate tissue react in the same 
concentration- dependent manner with the release of histamine, leukotrienes and PGD2 to 
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IgE- dependent triggers, we here use mast cell stimulation of nasal polyp tissue to study the 
effect of Syk inhibition of the allergic early phase reaction. 
 
The essential role of Syk has been proven in Syk-deficient murine mast cells, which are 
defective in receptor-induced degranulation, cytokine synthesis and intracellular signalling-
pathway activation10. Piceatannol, originally described as a Syk-selective inhibitor has been 
found to prevent mast cell degranulation in chopped lung fragments in guinea pigs11 and in 
human lung mast cells12.  Nowadays the more selective third-generation Syk inhibitors are 
used, resulting in more confident interpretation of results. 
One study demonstrated inhibition of histamine release in human basophils and cultured CD-
34+ mast cells, and showed inhibition of activation of human bronchial mast cells, assessed as 
less bronchial smooth muscle contraction in human isolated bronchial preparations. In this 
study a third-generation specific syk inhibitor (NVP-QAB205) was used13. 
Syk may represent an important target for the treatment of allergic rhinitis14. Since there is 
currently no data supporting this hypothesis, the aim of this study was to investigate the 
ability of NVP-QAB205 to inhibit the release of acute phase mediators in nasal polyp tissue 
after the stimulation of the high affinity IgE receptor.  
MATERIALS AND METHODS 
Patients 
Nasal polyp samples of 8 patients were collected at the Department of Otorhinolaryngology, 
Ghent University Hospital. The ethical committee of the Ghent University Hospital approved 
the study and informed consent was obtained from all subjects prior to inclusion in the study. 
None of the subjects used any intranasal corticosteroids within 1 week prior to surgery, nor 
took any oral and/or intramuscular corticosteroids within 4 weeks prior to surgery, nor anti-
histamines or anti-leukotrienes within 4 days prior to surgery, nor oral and intranasal 
decongestants or intranasal anticholinergics within 2 days prior to surgery. For the female 
subjects there was no current pregnancy or lactation. 
Samples were collected during functional endoscopic sinus surgery from 8 patients (median 
age 38.5 years, ranging from 20 to 54 years old, 4 female and 4 male patients). Nasal 
polyposis was diagnosed based on symptoms, clinical examination, nasal endoscopy, and 
sinus computed tomography (CT) scan according to the EP3OS guidelines15.  
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 The atopic status of all patients was evaluated by using skin prick tests with a standard panel 
of inhalant allergens. The reaction to a skin prick test was considered positive if the wheal 
area caused by the allergen was greater than 7 mm² (diameter >3 mm). Negative and positive 
controls (10 mg/ml histamine solution) were also included with each skin prick test. In the 
nasal polyp group there were 2 patients with an atopic status. None of the patients had asthma 
or aspirin intolerance in history. 
The nasal tissue collected during surgery was immediately transported to the laboratory for 
the ex-vivo stimulations. 
Syk Inhibitor NVP-QAB205  
The Syk inhibitor used in these studies (NVP-QAB205) was a kind gift from 
GlaxoSmithKline (Stevenage, United Kingdom) and its characteristics have been published16. 
In isolated enzyme assays this compound has an IC50 of 0.01M; hence at the concentrations 
tested here, it is a selective inhibitory tool. 
Mechanical disruption and stimulations of human nasal tissue 
Human nasal mucosa and submucosa was cut thoroughly in tissue culture medium consisting 
of RPMI 1640 (Sigma-Aldrich, Bornem, Belgium), containing 2mM L-Glutamine 
(Invitrogen, Merelbeke, Belgium), antibiotics (50 IU/ml penicillin and 50µg/ml streptomycin) 
(Invitrogen) and 0.1% BSA (Bovine Serum Albumin, Sigma). The tissue was passed through 
a mesh to achieve comparable fragments. The tissue fragments (+/- 0.9 mm3) were weighed 
and resuspended as 0.04g tissue/ 1 ml tissue culture medium.  
Tissue was preincubated for 1 hour at 37°C, 5% CO2 with 1µg/ml human myeloma IgE 
(Calbiochem, VWR International, Leuven, Belgium) and washed, tissue fragments were 
resuspended in the appropriate amount of culture medium, and 0.5 ml of the fragment 
suspension was dispensed per well in a 48 well plate (BD Falcon). The fragment suspensions 
were stimulated with either culture medium, or the Syk inhibitor NVP-QAB205 at 
concentrations of 10-8 M, 10-7 M, 10-6 M and 10-5 M for 1 hour. The DMSO concentration 
was kept constant at 0.1%. Following incubation with the inhibitor the fragments were 
stimulated with either tissue culture medium (negative control), or -chain specific anti-
human IgE antibody (Dako Belgium N.V., Heverlee, Belgium) at 10 or 30 µg/ml for 30 
minutes. All stimulations were done in duplicate.  
Supernatants were separated by centrifugation and stored immediately at -20°C until analysis 
of histamine, LTC4/D4/E4 and PGD2.  
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Cord Blood-Derived Mast Cell Culture and Activation Assay 
Cord blood-derived mast cells were differentiated from CD34+ progenitor cells (AllCells, 
Berkeley, California, USA), by culturing with stem cell factor (SCF), IL-6 and IL-10 
essentially as described by Ochi et al17.  
The medium used was RPMI 1640 (Sigma) containing 10% heat inactivated CELLect Fetal 
Bovine Serum (MP Biomedicals), 1% (0.1mM) non-essential amino acids 2 mM L-
Glutamine, 100U/ml Penicillin, 100g/ml Streptamycin , 10µg/ml Gentamicin, 200nM 2-
mercaptoethanol (All from InVitrogen), and 100ng/ml SCF, 50ng/ml IL-6, and 10ng/ml IL-10 
(all from Peprotech) for 12 weeks.  
For inhibitor assays (n=4), cells were plated at 5x104 cells/well in V-bottom 96-well tissue 
culture plates (Corning), and primed for 6 days 37°C, 5% CO2  in complete medium 
containing 10ng/ml IL-4 (Peprotech) and 2 µg/ml IgE (1μg/ml kappa,  1μg/ml lambda;  
Biodesign, AMS Biotechnology). Cells were then washed in assay buffer (RPMI containing 
additives as above but with only 4% FCS) and resuspended in 90μl of assay buffer per well. 
The Syk inhibitor was added in 10 μl of medium to give final concentrations ranging between 
10-9 M and 3x10-7 M, and incubated for 30 minutes at 37oC, 5% CO2. Anti-IgE antibody 
(Sigma) was then added in 10l to give a final concentration of 10g/ml and the plate was 
incubated for a further 30 minutes. The plate was then centrifuged at 1500 rpm in a bench 
centrifuge for 5 minutes to pellet cells, and supernatants were removed to a new plate, and 
centrifuged again that the supernatants were cell-free.  
Determination of mediator concentrations in supernatants 
Commercially available enzyme-linked immunosorbent assay (ELISA) kits were used to 
measure concentrations of histamine (IBL, Germany), LTC4/D4/E4 (Oxford Biomedical 
Research, Nuclilab BV, Ede, The Netherlands) and PGD2 (Cayman Chemicals, Ann Arbor, 
Michigan).  
Statistical analysis 
Statistical analysis was performed using the Wilcoxon test (for paired comparisons). P values 
of less than .05 were considered as statistically significant.  
94
Chapter VII - Syk-kinase inhibition prevents mast cell activation in nasal polyps 
  
RESULTS 
Effect of Syk Inhibitor on Mediator Release from CBDMCs 
Pre-incubation for 30 minutes with inhibitor resulted in significant inhibition of the release of 
histamine (Fig 1A, IC50 27.5 nM), leukotrienes (Fig 1B, IC50 22.5 nM) and PGD2 (Fig 1C, 
IC50 26.6 nM) in response to IgE receptor cross-linking induced by anti-IgE antibody. Here, 
the inhibitory potencies of the Syk inhibitor on the different mediators were similar. These 
efficacies correlated well with the activity of the inhibitor in in vitro kinase assays.  
  .  
 
 
Fig 1. Percent inhibition of mediator 
release after anti-IgE (10µg/ml) 
stimulation and increasing NVP-
QAB205 concentrations in cord 
blood derived mast cells. Inhibition 
of histamine release (A). Inhibition of  
LTC4/D4/E4 release (B). Inhibition of 
PGD2 release (C). Results are 
expressed as mean +/- SEM.  
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Effect of Syk Inhibitor on Mediator Release from Human Nasal Tissue 
Stimulation of nasal polyp tissue (n=8) with anti-IgE (10µg/ml and 30µg/ml) resulted in a 
dose-dependent release of histamine, cysteïnyl leukotrienes and PGD2 (Table 1). 
 
Effect of syk inhibitor on histamine release 
Increasing concentrations of Syk inhibitor (10-8 M, 10-7 M, 10-6 M and 10-5 M) significantly 
inhibited the release of histamine induced by 10µg/ml anti-IgE (p<0.02, p<0.01, p<0.02 and 
p<0.02 respectively) (IC50 13,6 nM). Also the nasal polyp tissue stimulated with 30µg/ml 
anti-IgE and preincubated with the Syk inhibitor, showed a significant decrease of histamine 
release, except for 10-8 M syk inhibitor (p<0.01, p<0.01 and p<0.01 respectively) (IC50 13,6 
nM) (Table 1 and Fig 2A).  
                              
Effect of syk inhibitor on LTC4/D4/E4 release 
In nasal polyps increasing concentrations of Syk inhibitor gave significant increasing 
inhibition of LTC4/D4/E4 release compared to anti-IgE 10µg/ml stimulation alone (p<0.05, 
p<0.01, p<0.01 and p<0.01 respectively) (IC50 5,7 nM) and compared to anti-IgE 30µg/ml 
stimulation alone (p<0.05, p<0.01, p<0.01 and p<0.01 respectively) (IC50 3,9 nM) (Table 1 
and Fig 2B).  
 
Effect of syk inhibitor on PGD2 release 
Furthermore, in nasal polyps the release of PGD2 was almost completely blocked after 
preincubation with increasing concentrations of Syk inhibitor (p<0.01, p<0.01, p<0.01 and 
p<0.01) in comparison with the release after stimulation with anti-IgE 10µg/ml alone (IC50 
80 nM). Also the nasal polyp tissue stimulated with 30µg/ml anti-IgE showed a significant 
dose-dependent decrease of PGD2 release (p<0.01, p<0.01, p<0.01 and p<0.01 respectively) 
(IC50 88 nM) (Table 1 and Fig 2C).  
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Fig 2. Percent inhibition of mediator release after anti-IgE 10µg/ml (  ) and anti-IgE 30 µg/ml (  ) 
stimulation and increasing NVP-QAB205 concentrations in nasal polyp tissue. Inhibition of histamine release 
(A). Inhibition of  LTC4/D4/E4 release (B). Inhibition of PGD2 release (C). Results are expressed as mean +/- 
SEM.  
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DISCUSSION  
 
The involvement of mast cells in upper airway disease such as allergic rhinitis is well 
established, but the current treatment modalities such as anti-histamines, anti-leukotrienes, 
and intranasal corticosteroids, are aimed at preventing the activity of single mediators, 
whereas the mast cell, upon activation by allergen, is able to produce a large number of 
inflammatory mediators whose activities will be unaffected by such drugs. There is therefore 
scope to improve on current treatments.  
 
Table 1. Overview of the effect of increasing concentrations of the Syk inhibitor on anti-IgE-induced release of 
histamine (ng/ml), LTC4/LTD4/LTE4 (ng/ml) and PGD2 (pg/ml) in the nasal polyp group (n=8). Data are 
expressed as mean +/- SD. 
 
________________________________________________________________________________________________________________ 
Stimulus                         release           +10-8 M syk inh        +10-7 M syk inh      +10-6 M syk inh     +10-5 M syk inh 
____________________________________________________________________________________________________
Histamine (ng/ml) 
 Baseline          24.4 +/- 11.9             23.8 +/- 11.9             22.2 +/- 12.3           21.1 +/-11.6      22.8 +/- 11.6  
     Anti-IgE 10µg/ml       42.3 +/- 16.8             37.0 +/- 16.7             32.2 +/- 14              28.1 +/-14.3      29.7 +/- 13.4 
     P-value*                                            0.0156                      0.0078                     0.0156                    0.0156 
     Anti-IgE 30µg/ml       63.0 +/- 20.6             51.6 +/- 24                39.2 +/- 15.3           36.4 +/-12.0 39.5 +/- 16.4  
     P-value*                                                       0.1484                      0.0078                     0.0078                      0.0078 
 
LTC4/LTD4/LTE4 (ng/ml) 
    Baseline                       0.08 +/- 0.04             0.07 +/- 0.03             0.07 +/- 0.04           0.06 +/- 0.03            0.07 +/- 0.04 
    Anti-IgE 10µg/ml        0.69 +/- 0.59             0.53 +/- 0.46             0.16 +/- 0.14           0.08 +/- 0.02            0.08 +/- 0.06 
    P-value*                                                        0.0391                      0.0078                     0.0078                      0.0078 
    Anti-IgE 30µg/ml        0.92 +/- 0.55             0.66 +/- 0.63             0.17 +/- 0.16           0.07 +/- 0.04            0.08 +/- 0.05 
    P-value*                                                        0.0234                      0.0078                     0.0078                      0.0078 
 
PGD2 (pg/ml) 
     Baseline                     168.0 +/-163.6          169.3 +/- 105.6         150.4 +/- 96.1          91.1 +/- 70.9            113.3 +/- 52.2  
     Anti-IgE 10µg/ml      2662.3 +/- 1793.3     1805.9 +/- 1170.7     1200.5 +/- 918.7      454.2 +/- 284.2        422.4 +/- 291.6 
     P-value*                                                      0.0078                       0.0078                     0.0078                      0.0078 
     Anti-IgE 30µg/ml      5205.5 +/-3575.5      3631.4 +/- 2543.6     2118.5 +/- 1566.9    1022.4 +/- 192.3      775.6 +/- 306.7 
     P-value*                                                      0.0078                       0.0078                      0.0078                     0.0078                                                       
____________________________________________________________________________________________________ 
* versus Anti-IgE stimulation (Statistical analysis; Wilcoxon-test) 
 
 
One such approach to improve upper airway disease therapies could be the discovery of 
potent and efficacious mast cell stabilisers, which would effectively block the production of 
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both early mediators (e.g. histamine, cysteinyl-leukotrienes, PGD2) and cytokines, which 
should relieve both immediate symptoms experienced on exposure to IgE-dependent triggers, 
but also halt the subsequent recruitment of inflammatory cells into the nasal mucosa. An 
understanding of the signalling pathways initiated upon cross-linking of the high affinity IgE 
receptor has helped identify potential future drug targets, and an example of one such protein 
is the tyrosine kinase Syk which appears to be critical for mast cell function. 
In order to evaluate the mast cell stabilisation potential of novel molecules such as Syk 
inhibitor NVP-QAB205, inhibition of mediator release of mast cells was here studied in cord 
blood derived mast cells and in nasal polyps. Our group recently developed a human nasal 
mucosal stimulation model with anti-IgE stimulations that mimics the allergic acute phase 
reaction9. Stimulations with anti-IgE on IgE-primed nasal tissue fragments lead to a dose-
dependent release of histamine, leukotrienes and PGD2 both in inferior turbinates and nasal 
polyps. In view of the mediators and the time course after stimulation, those outcome 
measures are specific for a mast cell response. As inferior nasal turbinate tissue in allergic 
rhinitis, nasal polyp tissue is characterized by the presence of effector cells such as mast cells 
and eosinophils, both typical for allergic inflammation18. As nasal polyps and inferior 
turbinate tissue react in the same concentration-dependent manner to IgE-dependent triggers, 
and nasal polyp tissue is easily provided by surgical procedures performed to remove disease, 
nasal polyp tissue was used in this pharmacological profiling setting9.  
Syk is not only expressed in mast cells19, 20 and basophils21, but also in eosinophils22, 
neutrophils23, macrophages24, dendritic cells25 and B-cells26.  
Syk has an essential role in immunoreceptor signalling. Allergen- specific IgE binds to the 
surface of mast cells and basophils through high affinity Fc receptors for IgE. Following 
subsequent allergen exposure, activation of mast cells and basophils through crosslinking of 
the tetrameric FcRI occurs and causes degranulation and de novo synthesis and release of 
mediators, all important in the allergic inflammation cascade. Receptor crosslinking results in 
the recruitment and the activation of cytoplasmatic kinase Lyn. Lyn causes tyrosine 
phosphorylation of ITAM in the cytoplasmatic domains of - and -chains. Phosphorylated 
ITAM in the -chains serve as binding sites for Syk SH2 domains. As a result of its binding to 
ITAM, syk becomes activated7, 10, 27. Activated Syk regulates multiple intracellular signalling 
pathways. Some important downstream targets of Syk in mast cells include phospholipase C 
(PLC), which may lead to mast cell degranulation, and the mitogen-activated protein kinase 
(MAPK) pathway which in turn may lead to leukotrienes and prostaglandine production8. 
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There is a growing body of literature of the importance of Syk in the development of allergic 
inflammation in the lower airways. In animal asthma models, aerosolized Syk antisense 
oligonucleotides (ASO) inhibited many of the central components (f.e. the level of 
eosinophils, tumour necrosis factor) of allergic asthma28, and a Syk-selective tyrosine kinase 
inhibitor prevented mast cell degranulation and airway hyperresponsiveness11, 29. In human 
lung mast cells piceatannol prevented histamine release12. Piceatannol was originally 
described as a syk-specific inhibitor but it inhibits other kinases as well30 and applied at 
concentrations inhibiting IgE-induced mediator release from basophils, it doesn’t act on syk31. 
Syk inhibitor NVP-QAB205 is considered selective for its respective kinase as it doesn’t 
inhibit other signaling steps thought to be downstream of Syk kinase such as ras-ERK 
pathway elements. It is known to have an IC 50 of 40 nM in human basophils and inhibition 
of Syk activity has no influence on either loss from the cell surface or degradation of the IgE 
receptor. Furthermore, it inhibits histamine release in cultured mast cells and it inhibits 
bronchial smooth muscle contraction 13, 32. 
  
Supplementary with the limited findings of Syk inhibition in the human bronchial biopsies, 
this study reports the potency of NVP-QAB205 to inhibit the release of acute phase mediators 
in human nasal tissue. The inhibitor was able to completely and potently inhibit mediator 
release from cord blood derived mast cells, thus enabling a comparison of its effect in nasal 
tissue fragments. 
In nasal polyps the syk inhibitor significantly inhibited the release of histamine, LTC4/D4/E4 
and PGD2. The IC50 values (13 nM for histamine, about 4.8 nM for leukotrienes and 80 nM 
for PGD2) were comparable to IC50 value of histamine in human basophils. In CBDMCs, the 
potencies of the Syk inhibitor on the different mediators are similar (pLTs=histamine=PGD2) 
however in nasal polyps they are different (pLTs>histamine>PGD2); probably due to the 
more complex physiological and disease-relevant system in human tissue. These are all mast 
cell products that may be detected immediately after exposure to allergens, causing typical 
symptoms such as rhinorrhea, sneezing, itching and nasal obstruction1. Furthermore, through 
the release of various inflammatory mediators, mast cells may contribute to the induction of 
eosinophilic inflammation and to the formation and progression of nasal polyps33. In nasal 
fluids from patients with nasal polyps, histamine levels are significantly higher than those 
observed in patients without nasal polyps34. In nasal polyps, preincubation with the syk 
inhibitor gave a 100% inhibition of the cysLTs production after anti-IgE stimulation and there 
was an almost total (+/-80%) inhibition of PGD2 production. There was also a significant 
100
Chapter VII - Syk-kinase inhibition prevents mast cell activation in nasal polyps 
  
decrease of histamine release; however the highest inhibition here was around 60%. The 
inhibition of the release of these mediators seemed to be dose-dependent. 
A clinical study, where another specific Syk inhibitor (R112) was applied, demonstrated the 
reduction of symptoms in seasonal allergic rhinitis patients 35. Our results suggest that this 
could be due to the inhibition of histamine, cysLTs and PGD2. 
 
In summary, syk activation is an important upstream event in the pathways activated through 
FcRI and may therefore control the synthesis and release of a whole range of mediators of 
both the early and late allergic responses. This study demonstrates that syk inhibition may 
prevent the degranulation of and the de novo synthesis in mast cells and in human nasal tissue. 
In future, specific syk inhibitors might provide a new therapeutic possibility in the treatment 
of upper airway disease with mast cell involvement such as allergic rhinitis. 
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ABSTRACT 
Background: Long term therapy with topical glucocorticosteroids is a hallmark therapeutic 
approach to control airway inflammation, but a complete suppression is seldom achieved. 
Targeting IKK-2 may circumvent this problem, and represents a growing area of interest, as 
within the last decade, small molecule inhibitors have become available. Nuclear Factor (NF) 
-kappaB is held inactive in the cytoplasm bound to I-kappaB. The removal of I-kappaB, via 
the actions of inhibitor of kappaB kinase-2 (IKK-2), allows NF-kappaB to enter the nucleus 
and regulate the expression of many inflammatory genes, including cytokines, chemokines, 
and adhesion molecules. Our aim was to determine the impact of IKK-2 inhibitors in 
comparison to the topical corticosteroid fluticasone propionate (FP) on the release of 
inflammatory cytokines, using nasal polyp tissue as a model. 
Methods: Surgical samples were collected from patients with nasal polyposis (n=8). Tissue 
fragments were preincubated for 1 hour with a specific IKK-2 inhibitor and FP in different 
concentrations and then stimulated with RPMI (negative control) or Staphylococcus aureus 
enterotoxin B (SEB) for 6 hours. Supernatants were measured by Multiplex for pro-
inflammatory cytokines (IL-1, tumor necrosis factor-) and T cell and subset related 
cytokines (interferon-, IL-2, IL-4, IL-5, IL-8, IL-10, IL-12p70, IL-13).  
Results: Stimulation with SEB for 6 hours resulted in a significant increase of IL-2, IL-4, IL-
5, IL-13, IFN-, IL-1 and TNF-. The IKK-2 inhibitor and FP were able to almost 
completely block the release of IL-4, IL-5 and IL-13. For IL-2 and IFN- FP had less impact 
than the IKK-2 inhibitor. Furthermore, the IKK-2 inhibitor could completely block the release 
of TNF- and IL1-, whereas FP had no effect on their release. 
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Conclusion: To conclude, inhibition of IKK-2 results in a reduction of the release of pro- 
inflammatory, Th1- and Th2- associated cytokines in nasal polyposis. Our results suggest that 
the IKK-2 inhibitor has a broader spectrum of inhibitory effects than FP, also including 
inhibition of pro-inflammatory cytokines. 
INTRODUCTION 
Nasal polyposis (NP) is a chronic inflammatory disease of the paranasal sinuses, associated 
with an increase of tissue eosinophils, Th-2 cytokines and IgE, and it is often associated with 
non-allergic late-onset asthma1. In the general population the prevalence of NP ranges from 1 
to 4% and the precise mechanism underlying the pathogenesis of NP is unknown and 
probably multifactorial. Treatment of NP with oral and topical corticosteroids and long-term 
antibiotics, each with different levels of evidence are described2.  
Topical corticosteroids sprays have a documented effect on the size of bilateral NP and also 
on symptoms associated with NP such as nasal blockage, secretion and sneezing but the effect 
on the sense of smell is not high2. Several studies underline the effect of fluticasone 
propionate (FP) to reduce nasal polyp size, reduce complaints of nasal obstruction and 
increase nasal airflow3, 4. Efficacy of treatment of NP with topical glucocorticosteroids is 
partly associated with their ability to reduce eosinophil viability and activation5, 6, and to 
reduce the secretion of chemotactic cytokines6, 7. In allergic rhinitis patients, FP reduces the 
secretion of several cytokines and chemokines after nasal allergen challenge8, 9. 
In NP an induced inflammatory resistance to steroid treatment with higher expression of GR 
isoforms has been described10, 11, however other data describe no correlation between 
expression of glucocorticoid receptor isoforms and nasal symptoms12. 
Despite all possible pharmacological treatments, NP remains a poorly controlled disease and 
when conservative treatment brings little or no lasting improvement, it often needs surgical 
intervention13.  Effective treatments such as the development of more specific and potent anti-
inflammatory agents that target the inflammation associated with NP are needed. 
 
NF-B is a major family of transcription factors activated during the inflammatory response. 
It is a key transcriptional regulator of multiple inflammatory mediators such as TNF-, 
interleukins, vascular cell adhesion molecules, etc.  In unstimulated cells, NF-B dimers are 
inactive, since they are sequestered in the cytoplasm by interaction with inhibitory proteins 
termed IBs (inhibitors of NF-B)14 . Phosphorylation and degradation of IBs allows NF-B 
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to translocate to the nucleus and to bind DNA to initiate gene expression15. The IB kinase 
(IKK)-complex, composed of 3 subunits (IKK-1, IKK-2 and NEMO)16, is responsible for this 
phosphorylation and degradation. 
IKK-2 is an important kinase for the control of inflammatory genes and recently 
pharmaceutically developed synthetic small molecule inhibitors of IKK-2, have become 
available17. IKK-2 inhibitors might prove useful in inflammatory and autoimmune disorders; 
however to our knowledge there are no reports on IKK-2 inhibition in NP.  
In inferior turbinates and NP, our group demonstrated a significant increase of several Th1, 
Th2 and pro-inflammatory cytokines after Staphylococcus aureus enterotoxin B (SEB) 
stimulation, with this increase significantly higher in NP compared to controls18. 
The current study aimed at evaluating the therapeutic potential of inhibiting the NF-B 
pathway. We wanted to determine the impact of IKK-2 inhibitors in comparison to the topical 
corticosteroid FP on the release of inflammatory cytokines, using nasal polyp tissue as a 
model. Their inhibitory properties on T-cell related cytokines (IFN-, IL-2, IL-4, IL-5, IL-8, 
IL-10, IL-12p70, and IL-13) and pro-inflammatory cytokines (IL-1, TNF-) were tested 
after stimulation with SEB. 
MATERIALS AND METHODS 
Patients 
Nasal polyp samples (n=8) were obtained from patients at the Department of 
Otorhinolaryngology of the University Hospital of Ghent. The ethical committee of the Ghent 
University Hospital approved the study and all patients gave their written informed consent 
prior to inclusion in the study. None of the subjects received intranasal corticosteroids, anti-
histamines or anti-leukotrienes, oral and intranasal decongestants or intranasal 
anticholinergics within 1 week prior to surgery and none of the subjects received oral and/or 
intramuscular corticosteroids within 4 weeks prior to surgery. For female subjects pregnancy 
or lactation was excluded. 
The nasal polyp samples were collected during functional endoscopic sinus surgery from 8 
patients (median age 44 years, ranging from 26 to 68 years old, 7 male and 1 female patient). 
Nasal polyposis was diagnosed based on symptoms, clinical examination, nasal endoscopy, 
and sinus computed tomography (CT) scan according to the EP3OS guidelines19. 
The atopic status of all patients was evaluated by skin prick tests with a standard panel of 14 
inhalant allergens. The reaction to a skin prick test was considered positive if the wheal area 
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caused by the allergen was greater than 7 mm² (diameter >3 mm). Negative and positive 
controls (10 mg/ml histamine solution) were included with each skin prick test. Two NP 
samples were obtained from patients with positive skin prick test for at least one of the most 
common aeroallergens. Two NP patients reported mild asthma in history, and one of them 
suffered of aspirin intolerance. One patient reported to smoke cigarettes. 
The nasal tissue collected during surgery was immediately transported to the laboratory and 
used for the ex-vivo stimulations.  
Mechanical disruption and stimulations of human nasal tissue 
The human nasal polyps were cut thoroughly in tissue culture medium consisting of RPMI 
1640 (Sigma-Aldrich, Bornem, Belgium), containing 2mM L-Glutamine (Invitrogen, 
Merelbeke, Belgium), antibiotics (50 IU/ml penicillin and 50µg/ml streptomycin) (Invitrogen) 
and 0.1% BSA (Bovine Serum Albumin, Sigma-Aldrich). The tissue was passed through a 
mesh to achieve comparable fragments. The tissue fragments (+/- 0.9 mm3) were weighed and 
resuspended as 0.04g tissue/ 1 ml tissue culture medium. Then 0.5 ml of this fragment 
suspension was dispensed per well of a 48 well plate (BD Falcon, VWR, Leuven). The 
fragments were then treated with either culture medium alone, the IKK-2 inhibitor (GSK 
657311A) at concentrations of 10-8 M, 10-7 M, 10-6 M and 10-5 M (based on preliminary 
experiments) or FP (GSK, Stevenage, UK) at concentrations of 10-10 M, 10-9 M, 10-8 M (based 
on preliminary experiments) for 1 hour. The DMSO concentration was kept constant at 0.1%. 
Following incubation with inhibitor and FP, the fragments were stimulated with either culture 
medium (negative control), or 0.5 µg/ml SEB (Sigma-Aldrich) for 6 hours. 
Supernatants were then removed and aliquots were stored immediately at -20°C until analysis 
of cytokines. The tissue was stored at -80°C. 
Measurements of mediators in supernatants of stimulated tissue fragments  
Concentrations of IL-1, TNF-, IFN-, IL-2, IL-4, IL-5, IL-8, IL-10, IL-12p70 and IL-13 
(2.4-10000 pg/ml) were measured on tissue supernatants obtained after the ex-vivo 
stimulations using Multi-spot assays (Meso Scale Discovery, Maryland, Gaithersburg) 
following the instructions of the manufacture. The plates were analysed using a Sector Imager 
6000 (Meso Scale Discovery). 
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Statistical analysis 
Statistical analysis was performed using the Wilcoxon test (for paired comparisons). P values 
of less than .05 were considered as statistically significant. The results of percentage 
inhibition were calculated based on the mean values corrected for baseline. 
RESULTS 
Stimulation with 0.5µg/ml SEB for 6 hours resulted in significant increase of IL-2 (p<0.01 ), 
IL-4 (p<0.01), IL-5 (p<0.05), IL-13 (p<0.01), IFN- (p<0.01), IL-1 (p<0.01) and TNF- 
(p<0.05); there was no increase of IL-8, IL-10 and IL-12p70, confirming earlier results18. 
 
Fig 1. Inhibition of the release of Th2 cytokines IL-4, IL-5 and IL-13 (pg/ml) after SEB stimulation (0.5 µg/ml) 
versus control samples. Inhibition with increasing concentrations of the IKK-2 inhibitor (A). Inhibition with 
increasing concentrations fluticasone propionate (B). * p<0.05, ** p<0.01.  Results are expressed as mean +/- 
SEM (standard error of the mean). 
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Fig 2. Inhibition of the release of 
Th1 cytokines IFN- and IL-2 
(pg/ml) after SEB stimulation (0.5 
µg/ml) versus control samples.. 
Inhibition with increasing 
concentrations IKK-2 inhibitor 
(A). Inhibition with increasing 
concentrations fluticasone 
propionate (B). * p<0.05, ** 
p<0.01.  Results are expressed as 
mean +/- SEM (standard error of 
the mean). 
Effect on Th2 cytokines 
After stimulation with 0.5µg/ml SEB, the IKK-2 inhibitor was able to almost completely 
block the release of IL-4, IL-5 and IL-13. A decrease of respectively 42% and 85% was 
observed for IL-4 following incubation with the IKK-2 inhibitor at 10-6 M and 10-5 M. For IL-
5 and IL-13 release, a blockage of respectively 90% and 85% was reached with the highest 
concentration (10-5 M) of the IKK-2 inhibitor (Fig 1A). 
Also for FP a significant inhibition of Th2 cytokine release was found, at a concentration of 
10-9M. FP 10-8 M demonstrated a decrease of IL-4, IL-5 and IL-13 of 82%, 80% and 82% 
respectively (Fig 1B) (IC50: table 1). 
Effect on Th1 cytokines 
Not only was the production of Th2 cytokines inhibited, but also that of Th1 cytokines. For 
IFN-, a higher inhibition was achieved with the IKK-2 inhibitor, reaching 80% inhibition at 
10-5 M (Fig 2A) versus only 47% inhibition with the highest concentration of FP (Fig 2B). 
For IL-2, an inhibition of 85% was achieved with the IKK-2 inhibitor at 10-5 M (Fig 2A) 
versus 34% with the highest concentration of FP (Fig 2B) (IC50: table 1). 
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Effect on pro-inflammatory cytokines   
With regard to the pro-inflammatory cytokines IL1- and TNF-, almost a complete 
inhibition of release was achieved with the IKK-2 inhibitor; 98% and 88%, respectively at  
10-5 M (Fig 3A). In contrast, no significant inhibition for IL1- and only a marginal, but 
significant inhibition of 25% was achieved by FP for TNF- (Fig 3B) (IC50: table 1). 
Furthermore, the spontaneous release of the pro-inflammatory cytokines, but also of IL-5, was 
decreased (baseline), especially after IKK-2 inhibition.  
 
Fig 3. Inhibition of the release of pro-inflammatory cytokines IL-1 and TNF- (pg/ml) after SEB stimulation 
(0.5 µg/ml) versus control samples. Inhibition with increasing concentrations IKK-2 inhibitor (A). Inhibition 
with increasing concentrations fluticasone propionate (B). * p<0.05, ** p<0.01.  Results are expressed as mean 
+/- SEM (standard error of the mean). 
DISCUSSION   
Nasal polyposis is a chronic inflammatory disease of the sinus mucosa and the middle 
turbinate often associated with non-allergic late onset asthma. Earlier studies demonstrated 
higher Th2 cytokines present in polyp tissue1, and stimulation with S. aureus derived 
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superantigen SEB further increases the Th2 bias and additionally increases Th1 cytokines and 
pro-inflammatory cytokines18. 
Long term therapy with potent intranasal glucocorticosteroids is frequently performed to 
control nasal polyp inflammation and growth, but the response to this treatment is often only 
partially successful and short courses of oral glucocorticosteroids or long-term antibiotics are 
periodically needed, mainly to quickly improve nasal obstruction. Despite this therapy, nasal 
polyps may progress and may require surgery. 
 
Table 1. IC50. Results are expressed as mean +/- SEM (standard error of the mean). 
 
    IC50 IKK-2 inhibitor   IC50 FP 
 
Th2 cytokines 
IL-4    5,4 .10-6 M (+/- 7,0.10-7 M)  7,0.10-10 M (+/- 1,4. 10-10 M) 
IL-5    3,0 .10-6 M (+/- 1,2.10-6 M)  4,8 .10-10 M (+/- 9,3.10-11 M) 
IL-13    5,9 .10-6 M (+/- 1,6.10-6 M)                1,5 .10-9 M (+/- 6,6.10-10 M) 
 
Th1 cytokines 
IFN-    2,6 .10-6 M (+/- 1,0.10-6 M)  3,2 .10-9 M (+/- 1,6.10-9 M) 
IL-2    3,8 .10-6 M (+/- 1,1.10-6 M)  not possible to calculate 
 
Pro-inflammatory cytokines 
IL-1    5,4 .10-7 M (+/- 9,3.10-8 M)  not possible to calculate 
TNF-    1,5 .10-6 M (+/- 8,2.10-7 M)  not possible to calculate 
 
 
For several years, a large number of kinases from different signal transduction pathways have 
been the target of interest for the treatment of inflammation and autoimmune disorders. One 
class of such kinases has been the IKK-2 (IB-kinase 2). The transcription factor Nuclear 
Factor kappa-B (NF-B) is known to be a master regulator of the expression of many 
inflammatory genes, including cytokines, chemokines, and adhesion molecules and upon 
activation of the cell following the stimulation of receptors such as the TNF receptor, Toll-
like receptors or the T-cell receptor (canonical pathway), a signal transduction cascade 
unravels. NF-B is held inactive in the cytoplasm, bound to I-B. The removal of I-B, via 
the actions of IKK-2, allows NF-B to enter the nucleus. 
In this regard, stimulation with SEB was used to demonstrate the possible effect of fluticasone 
propionate and an IKK-2 inhibitor in decreasing the production of Th1/Th2 or pro-
inflammatory cytokines14-16. 
 
Here, stimulation with SEB indeed led to a significant production of IL-2 , IL-4, IL-5, IL-13, 
IFN-, IL-1 and TNF-, confirming earlier results18 and inhibition of this production was 
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realized with an IKK-2 inhibitor. First of all, this is pointing out the importance of the NF-B 
pathway in the production of inflammatory cytokines in the superantigen-driven (SEB) 
stimulation. Moreover, this stimulation might concern specifically the canonical pathway as 
IKK-2 seems to play an important role and IKK-2 and NEMO are not required for NIK (NF-
B binding kinase) - induced p100 processing (alternative pathway)20.   
Superantigens are able to crosslink the class II major histocompatibility complex of antigen-
presenting cells and the T cell receptor -chain variable regions21. SEB stimulate T-cells both 
in humans and mice through the T cell receptor. Hence, here there is most likely a T-cell 
intrinsic NF-B activation after stimulation with SEB through the T cell receptor. 
  
Because of its critical role in canonical NF-B activation, IKK-2 has been the focus of 
considerable attention as an anti-inflammatory target. Inhibitors are expected to be efficacious 
in rheumatoid arthritis by affecting multiple mechanisms and cell types. In the murine 
collagen induced arthritis model they could inhibit disease severity and NF-B related 
cytokines (IL-1, IL-6, TNF- and IFN-)22-24. Furthermore, in inflammatory bowel diseases 
such as ulcerative colitis and Crohn’s disease, characterized by chronic relapsing 
inflammation, IKK-2 inhibitors ameliorated inflammatory responses in mice25. Additionally, 
IKK-2 inhibition could be beneficial in patients with type 2 diabetes because the activation of 
NF-B through IKK-2 induces inflammatory mediators that cause insuline resistance26. 
During insulin resistance tests in mice, IKK-2 inhibition dosed intraperitoneally significantly 
decreased plasma glucose levels27. Furthermore NF-B plays an essential role in the 
production of chemokines, cytokines and cell adhesion molecules in allergic asthma28. In 
mice, IKK-2 inhibition suppressed allergen-induced airway inflammation and hyperreactivity, 
with inhibition of airway eosinophilia, IL- 4, IL-5 and IL-1229. Similar results  were reported 
in an antigen-driven model of airway inflammation in rats and in human airway smooth 
muscle30, 31; IKK-2 inhibition decreased  inflammatory cell recruitment, TNF-, IL-1, IL-4, 
IL-5, IL-13 and eotaxin.  
To our knowledge, there are no reports on IKK-2 inhibition in nasal polyposis. However, the 
NF-B pathway may play an important role in this inflammatory disease. There is a higher 
gene and protein expression of NF-B in nasal polyps than in control mucosa, whereas 
transcription factor AP-1 does not seem to play a significant role in this pathological process32 
and the low expression of COX-2 mRNA in nasal polyps from aspirin-sensitive patients is 
associated with a down-regulation of NF-B activity33. 
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In this study, with the use of human nasal polyp tissue, we achieved similar results with the 
IKK-2 inhibitor as mentioned in the studies above, for the inhibition of IL-4, IL-5 and IL-13 
and here, the inhibitory effect of the IKK-2 inhibitor was comparable to the inhibitory effect 
of fluticasone propionate for those Th-2 cytokines. 
In regard of the inhibition of Th-1 cytokines, the IKK-2 inhibitor was able to block the 
production of IFN- and IL-2 almost completely, whereas fluticasone propionate only reached 
inhibition of around 40%. Similarly, in nasal lavage of allergic rhinitis patients after allergen 
challenge, fluticasone propionate caused a decrease of  IL-4, IL-5 and IL-13 and levels of IL-
2 and IFN- were not affected9.  
Furthermore, it could completely block the production of pro-inflammatory cytokines such as 
IL-1 and TNF- (98% and 88% respectively), whereas fluticasone propionate was 
practically unable to block these. Other studies demonstrated more or less similar results, for 
instance G-CSF (granulocyte-colony stimulating factor) release from primary airway smooth 
muscle is virtually steroid resistant, whereas it is completely blocked by IKK-2 inhibitors30 
and levels of TNF- are not affected by fluticasone propionate in allergic rhinitis patients 
after allergen challenge9. Interestingly, the spontaneous release of IL1- and TNF was 
decreased (baseline), especially after IKK-2 inhibition. As both IL1- and TNF- may 
activate NF-B this can be explained easily.  
There are concerns that inhibition of NF-B may cause side effects such as increased 
susceptibility to infection, which has been observed in gene disruption studies when 
components of NF-B are inhibited34, 35. Furthermore, it is suggested that IKK-2 may serve 
additional functions beyond regulating the NF-B pathway: the possibility has been raised 
that the IKK family is involved in control of normal mitosis 36, 37In addition, IKK-2 knockout 
mice do not survive due to liver apoptosis. The risks of chronic administration of IKK-2 
inhibitors in humans remain to be investigated. More information will become available as 
structurally distinct IKK-2 inhibitors progress through pre-clinical safety studies. 
 
To conclude, targeting IKK-2 represents a growing area of interest for researchers as small 
molecule inhibitors have recently become available. However, teratogenicity and 
susceptibility to infection could be problematic and therefore more research is necessary. 
Our results suggest that the IKK-2 inhibitor seemed, in certain respects, to possess a more 
comprehensive anti-inflammatory profile to that of fluticasone propionate in nasal polyposis. 
As in nasal polyposis, a subpopulation of patients was reported resistant to glucocorticoid 
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treatment11 and as short courses of oral glucocorticosteroids with possible side-effects are 
often necessary,  IKK-2 inhibition could give a more general treatment.  
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GENERAL DISCUSSION AND  
FUTURE PERSPECTIVES 
 
GENERAL DISCUSSION 
Discovery of novel drugs targeting kinases, an important class of intracellular enzymes that 
play a critical role in signal transduction pathways controlling a variety of cellular functions, 
has become the focus of a large number of drug discovery programs in the pharmaceutical and 
biotech industry. The approved drugs today have been useful for the treatment of a variety of 
cancers in human; kinase inhibitor discovery programs are now mainly focusing on drugs for 
the treatment of inflammation and autoimmune disorders, like rheumatoid arthritis, asthma, 
etc. Less is known about efficacy in nasal inflammatory pathologies. Kinase inhibitors have 
been tested in a lot of in vitro models, mainly animal models.  In this work we demonstrate 
models to test this kind of drugs in ex vivo human nasal tissue, which allows testing drugs in 
human disease relevant tissue in a kind of pre-safety and pre-clinical setting. We also test two 
kinase inhibitors in these models, namely a Syk inhibitor and an IKK-2 inhibitor. 
IgE-dependent early phase model 
In chapter V, we established a whole tissue nasal mucosal stimulation model which can be 
used to mimic the early phase of an allergic reaction both in nasal polyps and inferior 
turbinates. By using whole tissue preparations, the cells remained in their natural 
environment, and unchanged surface receptor expression was maintained by not using 
enzymatic digestion, thus closely mimicking the in vivo situation. These, in contrast to using 
exploration systems of rodent origin, use mast cell lines, or stimulate little amounts of human 
mast cells after positive isolation and the use of enzymatic digestion. Stimulations were done 
for 30 minutes with anti-IgE 10 µg/ml and anti-IgE 30 µg/ml in IgE primed nasal tissue 
fragments in order to study the acute response of the mast cell. Those stimulations resulted in 
a significantly higher production and release of mediators such as histamine, LTC4/D4/E4 and 
PGD2, all important in the early phase of an allergic reaction. These mediators were released 
in a concentration-dependent manner. After correction for spontaneous release, the induced 
release of histamine, LTC4/D4/E4 and PGD2 was significantly higher in the nasal polyp group 
compared to the inferior turbinate group, although tryptase, FcRI positive cells and 
FcRI-chain transcripts were equally present in both groups. No correlation was found 
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between baseline concentrations of IgE, and the release of histamine, LTC4/LTD4/LTE4 and 
PGD2 after stimulation. The nasal polyp tissue reacted in the same concentration-dependent 
manner as the inferior turbinate tissue. 
This IgE-dependent early phase model allows us to compare results obtained from nasal polyp 
tissue to inferior turbinate tissue. This is important in future settings as high amounts of nasal 
polyp tissue are easier to access. 
SEB-dependent late-phase model 
In chapter VI, we established a nasal polyp tissue stimulation model with SEB for late-phase 
release of numerous immunoregulatory and proinflammatory cytokines. SEB stimulation for 
30 minutes did not increase the release of cytokines, whereas 24 hours stimulation (late-
phase) resulted in a significant increase of IFN-, IL-2, IL-4, IL-5, IL-10, IL-13, TNF- and 
IL-1 in nasal polyps and inferior turbinates; and the release of these cytokines in nasal 
polyps was significantly higher compared to inferior turbinates, whereas no difference in the 
number of T lymphocytes could be found between inferior turbinates and nasal polyps. SEB 
did not show an effect on mast cell derived cytokines; after 30 minutes and 24 hours 
stimulation, no increase could be found of histamine, LTC4/D4/E4 and PGD2 in either group, 
which may prove the lack of direct effect of SEB in releasing mast cell mediators. However, 
as none of the samples were positive for IgE to SAEs, we could not explore the conventional 
allergen-mediated reaction in mast cells. Recently, we used this ex-vivo tissue model to test 
and investigate the anti-inflammatory effect on cytokines of new drugs.  
Furthermore, there is an increasing evidence that the colonization of S. aureus and the release 
of its cell products may be linked to the inflammation in nasal polyps1. In our study we further 
elucidated the disease-modifying role of S. aureus derived proteins SEB, SpA and LTA in 
nasal polyps. In the supernatants of tissue fragments cultured for 24 hours with medium alone, 
a significantly higher spontaneous release of IL-5 in nasal polyps compared to inferior 
turbinates was demonstrated, but no difference in IFN- release. In line with these results, 
significantly higher IL-5 protein concentrations versus controls, and no difference in IFN- 
concentrations in nasal polyp homogenates were found2. The relative increase in cytokine 
release after SEB stimulation in nasal polyps was the highest for IL-5, IL-4 and IL-2, but not 
for IFN-, demonstrating skewing towards a Th-2 polarisation pattern. The relative increase in 
cytokine release was the lowest for IL-10 and TGF-1, indicating a possible lack in T-cell 
regulation induced by SEB. A more recent study of our group could confirm these results. A 
decreased expression of FOXP3 (transcription factor for T regulatory cells) was found in 
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nasal polyps together with low levels of TGF-1 protein expression, reflecting a deficiency or 
dysfunction of Treg cells3. 
In contrast to SEB, our results demonstrate an “allergenic” effect of SpA, a surface protein on 
S. aureus. Its activity is mediated by interaction with the commonly expressed VH3 region of 
IgE, bound to the FcRI4.  After 30 minutes stimulation with SpA, inferior turbinate and nasal 
polyp tissue did give a significant increase of histamine, LTC4/D4/E4 and PGD2 and no 
increase of cytokines. After 24 hours, the production of cysLTs remained significantly 
increased and also IL-5 was significantly increased. 
LTA stimulation on nasal tissue did not induce any increase of Th1/Th2 cytokines, pro-
inflammatory cytokines or mast cell derived mediators, clearly reflecting the limited role of 
LTA in the inflammatory scene in nasal polyps. 
These data support the hypothesis that S. aureus may be linked to the inflammation in nasal 
polyposis. Not only SEB, but also SpA may prove factors in causing or exacerbating the 
inflammation in nasal polyposis.  
Syk-kinase inhibition 
The cross-linking of the high affinity IgE receptor activates mast cells and basophils. As 
spleen tyrosine kinase is positioned upstream of the IgE receptor signal transducing pathway, 
therapies targeting Syk should block three mast cell functions: The release of preformed 
mediators such as histamine, the production of lipid mediators such as leukotrienes and 
prostaglandins and the secretion of cytokines5. Therefore, the inhibition of Syk may represent 
an important target for the treatment of nasal inflammatory diseases. 
In chapter VII we looked at the effect of a specific Syk inhibitor to inhibit the release of early 
phase mast cell mediators in human cord blood-derived mast cells (in-vitro) and in human 
nasal polyp tissue (ex-vivo). The IgE-dependent early phase model was used to test this 
inhibiting effect.  
In cord blood-derived mast cells the Syk inhibitor significantly prevented the degranulation, 
assessed by measurement of histamine release, and the production of LTC4/LTD4/LTE4 and 
PGD2. Furthermore, the Syk inhibitor was similarly able to significantly inhibit histamine, 
LTC4/LTD4/LTE4 and PGD2 in nasal polyp tissue in a dose dependent manner. In cord blood-
derived mast cells, the potencies of the Syk inhibitor on the different mediators were similar 
(pLTs=histamine=PGD2); however in nasal polyps they were different 
(pLTs>histamine>PGD2), probably due to the more complex physiological and disease-
relevant system in human tissue. 
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Supplementary with the limited findings of Syk inhibition described in the human bronchial 
biopsies6, our study reports the potency of a specific selective Syk inhibitor (NVP-QAB205) 
to inhibit the release of acute phase mediators in human nasal tissue. A clinical study, where 
another specific Syk inhibitor (R112) was applied, demonstrated the reduction of symptoms in 
seasonal allergic rhinitis patients 7. Our results suggest that this could be due to the inhibition 
of histamine, cysLTs and PGD2. 
We suggest that in future, specific Syk inhibitors might provide a new therapeutic possibility 
in the treatment of upper airway diseases with mast cell involvement, such as allergic rhinitis. 
IKK-2- kinase inhibition 
Targeting IKK-2 represents a growing area of interest for researchers and pharmaceutical 
firms as, during the last decade, small molecule inhibitors have become available. IKK-2 is an 
important kinase in the NF-B pathway. Inhibition of this kinase could therefore result in the 
blockage of transcription of multiple inflammatory mediators, such as TNF-, interleukins, 
cell adhesion molecules, etc. Long term therapy with potent intranasal or oral corticosteroids 
is frequently performed to control nasal polyp inflammation and growth, but the response to 
this treatment is often only partially successful and oral corticosteroids may cause multiple 
side-effects. 
In chapter VIII our goal was to determine, in nasal polyposis, the impact on the release of 
several Th1, Th2 and pro-inflammatory cytokines when inhibiting IKK-2 in comparison to the 
impact of the topical corticosteroid fluticasone propionate. We used the SEB-dependent late 
phase model to test these inhibitory properties and we could demonstrate that the IKK-2 
inhibitor and fluticasone propionate were able to almost completely block the release of IL-4, 
IL-5 and IL-13. In regard of the inhibition of Th-1 cytokines, the IKK-2 inhibitor was able to 
block the production of IFN- and IL-2 almost completely, whether fluticasone propionate 
only reached an inhibition of around 40%. Furthermore, the IKK-2 inhibitor could completely 
block the production of pro-inflammatory cytokines such as IL-1 and TNF-, whereas 
fluticasone propionate was practically unable to block these. Our results suggest that the IKK-
2 inhibitor seemed, in certain respects, to possess a more comprehensive anti-inflammatory 
profile than that of fluticasone propionate in nasal polyposis. In the future IKK-2 inhibition 
could be of interest for the treatment of nasal polyposis. However, the risks of chronic 
administration of IKK-2 inhibitors in humans remain to be investigated as side-effects such as 
teratogenicity and susceptibility to infection could be problematic. More information will 
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become available as structurally distinct IKK-2 inhibitors progress through pre-clinical safety 
studies. 
FUTURE PERSPECTIVES 
In the future, these kinds of stimulation models make it possible to test drugs in human 
disease relevant tissue in a kind of pre-safety and pre-clinical setting.  
In general, we will be able to test different kinds of promising selective pharmaceutical 
compounds. Moreover, these kinds of stimulation models give us the opportunity to test 
different molecules of the same compound on human tissue. In this respect small differences 
in potency can be detected.  
Currently, we are using the early and the late phase model to test Compound A (corticosteroid 
-like extract from plants), PDE-4 inhibitors (phosphodiesterase-4) and CRAC (Ca2+ release-
activated Ca2+) channels inhibitors.   
Furthermore, we can use these stimulation models on other tissues. Currently there are studies 
ongoing to stimulate gut tissue and to test relevant inhibitors.  
These stimulation models may also be used in more fundamental research settings. We used 
the supernatants from anti-IgE stimulated polyp tissue to demonstrate that PGD2 produced by 
mast cells promotes the migration of Th2 cells through a CRTH2 (chemoattractant receptor-
homologous receptor expressed on Th2 cells) dependent mechanism8.  
 
Development of new nasal tissue models: First of all an ex-vivo late phase model should be 
set up to stimulate mast cells in inferior turbinates and nasal polyps by using IgE/ anti-IgE 
specific ( chain specific) stimulations and measure production of several late phase cytokines 
(i.e. IL-4, IL-5, IL-6, TNF-, IL-13). This would be very interesting to test new molecules 
with potential in treating allergic rhinitis. We tried to set up this model and we could achieve 
a significant release of IL-5 and IL-13 in nasal polyps; however, until now we have not been 
able to set up a late phase anti-IgE model in inferior turbinates; further studies are necessary.  
Recently, we have established a model with specific allergen stimulations9. Allergen 
stimulation with different concentrations of grass pollens, in inferior turbinate and nasal polyp 
tissue with specific IgE to grass pollen, led to the release of PGD2 in a Gaussian distribution. 
Interestingly, in nasal polyp tissue there was a lower release of PGD2 after grass pollen 
stimulation compared to the PGD2 release in inferior turbinate. This in contrast to the 
significantly higher release of PGD2 in nasal polyps after anti-IgE stimulation.  Moreover, in 
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this recent study we could demonstrate the direct effect of SEB in releasing mast cell 
mediators in samples positive for IgE to SAEs. 
 
Finally, the therapeutic purposes for kinase inhibitors will be further explored. On the one 
hand, inhibition of Syk kinase activity, using small molecules is one approach. On the other 
hand, although early in the pharmaceutical development stage, suppression of Syk gene 
expression appears to be a viable approach to reduce allergic responses. Regulation of Syk 
gene expression can be targeted using siRNA (small interfering RNA) technology. In 
cooperation with GSK, we will investigate the feasibility of delivering RNAi (RNA 
interference) to nasal tissue fragments, look at the maintenance of a mast cell response after 
RNAi delivery and investigate significant functional inhibition of the mast cell response. 
Further studies will be needed to evaluate these kinds of therapies in terms of efficacy and 
safety. 
 
 
 
 
GENERAL CONCLUSIONS 
This thesis evaluates models to test drugs in human-disease-relevant-nasal tissue in a pre-
safety and pre-clinical setting, and demonstrates the effect of two kinase inhibitors namely a 
Syk inhibitor and an IKK-2 inhibitor. A whole tissue nasal mucosal anti-IgE stimulation 
model, which can be used to mimic the early phase of an allergic reaction, was set up both in 
nasal polyps and inferior turbinates, and a SEB tissue stimulation model for late-phase release 
of numerous immunoregulatory and proinflammatory cytokines was established. 
Additionally, we have shown that SEB and SpA contribute to the Th-2 polarisation pattern 
and the mast cell degranulation in nasal polyps, respectively. 
The Syk inhibitor we tested significantly inhibited histamine, leukotrienes and PGD2. 
Furthermore, our results suggest that the IKK-2 inhibitor has a broader spectrum of inhibitory 
effects than fluticasone propionate, also including inhibition of pro-inflammatory cytokines. 
In the future, the Syk - and the IKK-2 inhibitor might therefore be further developed as new 
therapeutics targets. 
 
123
General discussion and future perspectives 
 
REFERENCES 
1. Van Zele T, Gevaert P, Watelet JB, Claeys G, Holtappels G, Claeys C, et al. Staphylococcus aureus 
colonization and IgE antibody formation to enterotoxins is increased in nasal polyposis. J Allergy Clin 
Immunol 2004; 114:981-3. 
2. Van Zele T, Claeys S, Gevaert P, Van Maele G, Holtappels G, Van Cauwenberge P, et al. 
Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy 2006; 
61:1280-9. 
3. Van Bruaene N, Perez-Novo CA, Basinski TM, Van Zele T, Holtappels G, De Ruyck N, et al. T-cell 
regulation in chronic paranasal sinus disease. J Allergy Clin Immunol 2008; 121:1435-41, 41 e1-3. 
4. Genovese A, Bouvet JP, Florio G, Lamparter-Schummert B, Bjorck L, Marone G. Bacterial 
immunoglobulin superantigen proteins A and L activate human heart mast cells by interacting with 
immunoglobulin E. Infect Immun 2000; 68:5517-24. 
5. Wong BR, Grossbard EB, Payan DG, Masuda ES. Targeting Syk as a treatment for allergic and 
autoimmune disorders. Expert Opin Investig Drugs 2004; 13:743-62. 
6. MacGlashan D, Jr., Undem BJ. Inducing an anergic state in mast cells and basophils without secretion. 
J Allergy Clin Immunol 2008; 121:1500-6, 6 e1-4. 
7. Meltzer EO, Berkowitz RB, Grossbard EB. An intranasal Syk-kinase inhibitor (R112) improves the 
symptoms of seasonal allergic rhinitis in a park environment. J Allergy Clin Immunol 2005; 115:791-6. 
8. Perez-Novo CA, Holtappels G, Vinall SL, Xue L, Zhang N, Bachert C, et al. CRTH2 mediates the 
activation of human Th2 cells in response to PGD(2) released from IgE/anti-IgE treated nasal polyp 
tissue. Allergy; 65:304-10. 
9. Zhang N, Holtappels G, Gevaert P, Patou J, Dhaliwal B, Gould H, et al. Mucosal tissue polyclonal IgE 
is functional in response to allergen and SEB. Allergy. 
 
 
124
Curriculum Vitae 
CURRICULUM VITAE 
________________________________________________________ 
 
 
Familienaam:             Patou 
Naam:  Joke Agnes Erik 
Geboortedatum:         13 april 1979 
Geboorteplaats:           Brugge 
Nationaliteit:  Belg 
Burgelijke staat: Gehuwd, 2 kinderen 
Thuisadres:             Steenakker 11 
9000 Gent 
België 
E-mail:   jokepatou@hotmail.com 
 
 
ONDERWIJS 
 
 Secundair onderwijs: St.-Jozef Humaniora, Brugge 
  1991-1997: Grieks-Latijn / Wiskunde-Wetenschappen 
 
 Basisopleiding arts: Universiteit Gent, 1997- 2004 
  * Inleefstage, Kameroen, augustus-september 2000 
  * Erasmusstage, Amsterdam, VU, mei-juli 2003 
 
 Certificaat elektrocardiogram: Universiteit Gent, 2002 
 
 Certificaat  Radioprotectie: Universiteit Gent, 2004 
 
 Arts specialist in opleiding otorhinolaryngologie: Universiteit Gent, 2004 -2011 
* Full time wetenschappelijk onderzoek, september 2004 -maart 2007, Upper 
airways research laboratory 
* Dienst neus-, keel-, oorheelkunde en hoofd- en halschirurgie Universitair 
Ziekenhuis Gent, april 2007-september 2008 
* Dienst neus-, keel-, oorheelkunde AZ St.- Lucas Gent, oktober 2008 -
september 2009 
* Dienst neus-, keel-, oorheelkunde en hoofd-en halschirurgie Universitair 
Ziekenhuis Gent, oktober 2009 -juli 2011 
  
  
PUBLICATIES 
 
Zhang N, Gevaert P, Van Zele T, Perez-Novo C, Patou J, Holtappels G, Van Cauwenberge P, 
Bachert C. An update on the impact of Staphylococcus aureus enterotoxins in chronic 
sinusitis with nasal polyposis. Rhinology 2005; 43: 162-168. 
 
Bachert C, Patou J, Van Cauwenberge P. The role of sinus disease in asthma. Curr Opin 
Allergy Clin Immunol. 2006 Feb; 6(1):29-36.  
 
125
Curriculum Vitae 
Patou J, De Smedt H, Van Cauwenberge P, Bachert C. Pathophysiology of nasal obstruction 
and meta- analysis of early and late effects of levocetirizine. Clinical and experimental allergy 
2006; 36: 972-981 
 
Bachert C, Zhang N, Van Zele T, Gevaert P, Patou J, Van Cauwenberge P. Staphylococcus 
aureus enterotoxins as immune stimulants in chronic rhinosinusitis. Clin Allergy Immunol. 
2007; 20:163-75.  
 
Patou J, Gevaert P, Van Zele T, Holtappels G, Van Cauwenberge P, Bachert C. 
Staphylococcus aureus enterotoxin B, protein A and lipoteichoic acid stimulations in nasal 
polyps. Journal of allergy and clinical immunology 2008 Jan; 121:110-5. 
 
Bachert C, Zhang N, Patou J, Van Zele T, Gevaert P. Role of staphylococcal superantigens in 
upper airway disease. Curr Opin Allergy Clin Immunol. 2008 Feb; 8(1):34-8. 
 
Patou J, Holtappels G, Affleck K, Gevaert P, Perez-Novo C, Van Cauwenberge P, Bachert C. 
Enhanced release of IgE-dependent early phase mediators from nasal polyp tissue. J Inflamm. 
2009 Apr; 20:6-11. 
 
Huvenne W, Van Bruaene N, Zhang N, Van Zele T, Patou J, Gevaert P, Claeys S, Van 
Cauwenberge P, Bachert C. Chronic rhinosinusitis with and without nasal polyps: what is the 
difference? Curr Allergy Asthma Rep. 2009 May; 9(3):213-20.  
 
Zhang N, Holtappels G, Gevaert P, Patou J, Dhaliwal B, Gould H, Bachert C. Mucosal tissue 
polyclonal IgE is functional in response to allergen and SEB. Allergy. 2011 Jan; 66:141-8. 
 
Patou J, Holtappels G, Affleck K, Van Cauwenberge P, Bachert C. Syk-kinase inhibition 
prevents mast cell activation in nasal polyps. Rhinology. 2011 March; 49:100-6. 
 
 
PRESENTATIES OP CONGRESSEN 
 
Mondelinge Presentaties 
 
1 oktober 2005, Modern research in sinus disease and allergic rhinitis. Presentation Skills 
Master Class, UZ Gent: “Pathomecanisms of allergic rhinitis” Patou J. 
 
18 november 2005, Koninklijke Belgische Vereniging voor Otorhinolaryngologie, Gelaat- en 
Halschirurgie, From opinion to advice, Congress Palace,  Luik: “Intraepithelial presence of 
Staphylococcus aureus in nasal polyps” Patou J, Van Zele T, Holtappels G, Claeys S, Gevaert 
P, Cuvelier C, Van Cauwenberge P, Bachert C. 
 
25 november 2005, Superantigens in airway disease: Immunology and clinics of 
superantigen-driven inflammation, Novotel Hotel, Gent: “Intraepithelial presence of 
Staphylococcus aureus in nasal polyps” Patou J, Van Zele T, Holtappels G, Claeys S, Gevaert 
P, Cuvelier C, Van Cauwenberge P, Bachert C. 
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activation” Patou J, Holtappels G, Gevaert P, Van Cauwenberge P, Bachert C. 
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20 mei 2006: Koninklijke Belgische Vereniging voor Otorhinolaryngologie, Gelaat- en 
Halschirurgie, Wetenschappelijke Vergadering, Gasthuisberg, Leuven: “Inhibition of protein 
tyrosine kinase activity in an ex-vivo nasal challenge model” Patou J, Holtappels G, 
Thompson N, Van Cauwenberge P, Bachert C. 
 
26 februari 2007: 63rd Annual Meeting of the American Academy of Allergy, Asthma and 
Immunology (AAAAI), San Diego, California, United States: “Protein A, SEB and LTA 
stimulations in nasal polyps” Patou J, Van Zele T, Gevaert P, Holtappels G, Williamson R, 
Van Cauwenberge P, Bachert C. 
 
4 november 2010: European Rhinitis and Asthma Meeting Symposium on Experimental 
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inhibition in nasal polyps” Patou J, Holtappels G, Afleck K, Gevaert P, Bachert C. 
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juni 2005: XXIV Congres of the European Academy of Allergology and Clinical 
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Claeys S, Gevaert P, Van Cauwenberge P, Bachert C. 
 
februari 2006: 4th EAACI and GA2LEN Davos Meeting, Basic Immunology Research in 
Allergy and Clinical Immunology, Garmish-Partenkisrchen, Germany: “Ex-vivo nasal 
challenge model to investigate mast cell activation” Patou J, Holtappels G, Gevaert P, van 
Cauwenberge P, Bachert C. 
 
juni 2006: XXV Congress of the European Academy of Allergology and Clinical 
Immunology (EAACI), Vienna, Austria: “Ex-vivo model to challenge and investigate nasal 
mast cell activation” Patou J, Holtappels G, Gevaert P, Van Cauwenberge P, Bachert C.  
 
29 september-2 oktober 2006, EAACI and GA2LEN Allergy school, Hannover, Germany: 
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Patou J, Holtappels G, Thompson N, Affleck K, Gevaert P, Van Cauwenberge P, Bachert C. 
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________________________________________________________ 
 
Mijn doctoraat is af ! Voor mij is dit een mooi eindresultaat van mijn jaren intensief 
wetenschappelijk onderzoek. Niet alleen mijn wetenschappelijke carrière in het UZ sluit ik 
hiermee af, maar ook mijn “zorgeloze”assistentenjaren. Een afscheidsfeestje, familieverhuis, 
nieuwe woning en nieuw werk staan voor de boeg: een spannende uitdaging! 
Op dit punt zou ik nooit geraakt zijn zonder de steun van heel veel mensen. 
 
Prof Claus Bachert, mijn promotor. U kwam met de opdracht (het leek een onmogelijke 
opdracht) om te zoeken naar een “weefsel-stimulatie-model” en u liet me hierin de volledige 
vrijheid. Op de gepaste momenten kreeg ik feedback en een enthousiast duwtje in de rug om 
vol te houden en door te zetten. Uw motivatie om de ziekte neuspoliepen wereldwijd in kaart 
te brengen, uw dagelijks enthousiasme en goedlachsheid zullen me altijd bijblijven.  
 
Prof Philippe Gevaert, mijn copromotor. Jij bent al even gebeten door het wetenschappelijk 
virus als prof. Bachert. Bij jou kon ik altijd terecht met eender welke vraag. Ook als ik het nut 
van een doctoraat eventjes niet meer inzag, kon jij me toch telkens weer oppeppen en op het 
juiste spoor zetten. Jij zorgde er ook voor dat ik als prille wetenschapper de kans kreeg om 
naar congressen in het buitenland te gaan, wat natuurlijk een enorme wetenschappelijke boost 
was. Mijn eerste congres in Amerika in San Antonio met zijn riverwalk vergeet ik nooit! 
 
Gabi Holtappels, zonder jou was dit doctoraat er nooit geweest, en dat meen ik! Jouw secuur 
werk en jarenlange ervaring zorgden voor exacte resultaten. Het klikte tussen ons, we waren 
echte doorzetters en van opgeven was er geen sprake. We zochten samen naar allerlei 
methoden om het “stimulatiemodel” op punt te zetten en het duurde uiteindelijk praktisch één 
jaar voor we de eerste reproduceerbare resultaten hadden, nadien verliep het gelukkig wat 
vlotter. Ook wanneer er een traantje vloeide, kon jij voor mij de zaken in een ander daglicht 
plaatsen. Ondanks mijn drukke klinische activiteiten en gezinsleven, stond je altijd direct 
paraat om mij verder te helpen met mijn doctoraat. Bedankt voor alles... 
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Alle leden van de examen- en leescommissie: Prof Cuvelier, Prof Hellings, Prof Van 
Winckel, Prof De Paepe, Prof Joos, dr. Dullaers, Prof Louis . Hartelijk dank om mijn 
doctoraat grondig na te lezen  en constructieve opmerkingen te geven. 
 
De eerste maanden van mijn wetenschap kwam ik terecht in een klein bureautje in blok B 
samen met Jeroen en Thibaut. Al snel volgde de verhuis naar het MRB (medical research 
building), waar Wouter en Nicholas mijn vaste “bureaupartners” werden. Speciale dank aan 
jullie alle vier, om er voor mij een toffe wetenschapstijd van te maken. Jullie beseffen als 
geen ander hoe hard het soms kan zijn om als assistent en dan vooral tijdens de kliniekjaren 
verder wetenschappelijk werk te doen. Bedankt ook aan alle mensen uit het labo, voor alle 
babbels en voor de vlotte en aangename samenwerking. 
Karen Affleck en Nicki Thompson, met jullie hield ik maandelijks “telephone conferences” 
om de stand van zaken door te nemen. Bedankt voor jullie input en in het algemeen bedankt 
aan GSK om jullie moleculen te kunnen uittesten. 
 
Daarnaast wens ik ook alle proffen, stafleden en residenten te bedanken voor de dagelijkse 
teaching en in het algemeen, voor gans mijn opleiding NKO. Prof Van Cauwenberge, Prof 
Dhooge, Prof Vermeersch, Prof Bachert, Prof Gevaert, Prof Claeys, Prof Watelet, Prof 
De Leenheer, Dr Bonte, Dr Deron, Dr Domjan, Dr Van Zele, Dr Van Hoecke en Dr 
Loose.  
Bedankt ook aan alle collega’s voor de dagelijkse leuke werksfeer, voor een luisterend oor en 
voor alle vriendschap. Laurence De Coster, Leen Van Crombrugge, Nicholas Van 
Bruaene, Wouter Huvenne, Lien Calus, Evelien Van Houtte, Lien Devuyst, Tineke 
Dutre, Peter Tomassen, Julie Goderis, Griet Vandenplas en Jeroen Clement, Katia 
Verbruggen en Joke Huyghe. 
Vervolgens ook een dank u wel voor alle medewerkers van de dienst NKO: het verplegend 
personeel, het secretariaat, de audiologen en logopedisten. Bedankt voor de aangename 
samenwerking, de gezellige middagpauzes en de leuke babbels. 
 
Hierbij wil ik ook de gelegenheid aangrijpen om al mijn vriendinnekes eens te bedanken. 
Bedankt voor alle toffe momenten: feestjes, babyborrels, meidenweekends, telefoontjes,... 
Tussen mijn drukke werk- en gezinsleven zorgen jullie gelukkig voor de nodige ontstress- en 
luistermomenten. 
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Natuurlijk wil ik boven alles ook mijn familie bedanken. Lieve mama en papa, wat jullie 
allemaal doen voor mij is ongelooflijk! Waar ik nu sta in mijn leven is ongetwijfeld te danken 
aan de vrijheid, steun en onvoorwaardelijke liefde die jullie me altijd gegeven hebben.  
Ook dankjewel aan Dieter en Ine, mijn grote broer en kleine zus, en aan mijn schoonzussen 
en –broers, dat jullie er zijn voor mij en de familie maken zoals ze nu is. Ook dank aan mijn 
schoonouders om wanneer nodig onze kindjes op te vangen. 
 
Niels en Xander, mijn lieve schatten, jullie beseffen nog niet waarmee jullie mama allemaal 
bezig is, misschien gelukkig maar. Jullie lach, zoentjes en knuffels, er zijn voor jullie, maken 
mij zo gelukkig en geven mij de moed en kracht om elke dag alles te geven. En dan, mijn 
keppie, Tom. Het klinkt misschien cliché, maar jij bent mijn steun en toeverlaat. Zonder 
morren nam je de vele dagdagelijkse dingen over zodat ik nog eventjes kon doorwerken aan 
mijn doctoraat. Je maakt mij intens gelukkig, en dat meen ik! Ik zie je graag. 
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